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CHAPTER 1 
GENERAL INTRODUCTION AND SCOPE OF THE THESIS 

Delineation of Genetically Determined Mental Retardation 
Mental retardation, defined by an intelligence quotient (IQ) below 70, is a 
common and distressing disorder which occurs in approximately 1-3 per cent 
of the general population (Hagberg et al., 1983; WHO, 1986). Mentally 
retarded individuals can be grouped into two classes: (i) those that are 
severely affected (IQ <50) and (ii) those that are mildly affected (IQ 50-70). 
Studies on the etiology of mental retardation have shown that the genetic 
contribution to severe mental retardation ranges from 25 to 52%, while for 
mild mental retardation about 7% may be caused by genetic factors 
(Gustavson, 1977; Roeleveld, 1992). Since a disproportionate excess (25%) of 
males was observed in various mentally retarded populations, it was 
considered likely that an X-linked pattern of inheritance was involved. 
Further support for the notion of an X-linked defect in a distinct subgroup of 
mentally retarded males was obtained by the identification of a number of 
nuclear families with an excess of male patients (Martin and Bell, 1943; Allan 
et al., 1944; Losowsky, 1961; Dunn et al., 1963; Renpenning et al., 1962; 
Snyder and Robinson, 1969; Lubs, 1969). Definite contributions to the 
delineation of X-linked mental retardation (XLMR) were made in the early 
1970s by Lehrke (1972, 1974) and Turner & Turner (1974). Lehrke (1974) 
emphasized that XLMR may be responsible for 25 to 50% of the overall 
occurrence of mental retardation. Approximately one-third of these cases 
appeared to be due to the presence of the fragile X (fra(X)) syndrome (Turner 
et al., 1986; Webb, 1989). 
Clinical and Social Phenotype of Fra(X) Syndrome 
Studies on intelligence levels have shown that most affected fra(X) males 
are severely retarded (IQ 20-50) (Chudley et al., 1983; Kähkönen et al., 
1983; Fryns et al., 1984, 1989; Veenema et al., 1987), but also higher 
functioning males do exist (Hagerman et al., 1994). Longitudinal observations 
indicate that IQ scores among fra(X) males decline later in life (Lachiewicz et 
al., 1987; Hagerman et al., 1989; Curfs et al., 1989; Fisch et al., 1991). 
The most prominent physical features in affected adult fra(X) males (fig. 1) 
include an oblong face, large head circumference in early childhood, long and 
protruding ears, prominent jaw, extensible joints and macro-orchidism 
(Turner et al., 1980; Sutherland and Hecht, 1985; Hagerman et al., 1987). 
Many of these features become obvious in puberal males, although an 
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Fig. 1. Appearance of a typical fra(X) patient. Note the oblong face and 
prominent jaw. 
extensive variability in physical and psychological expression can be 
observed, even between brothers (see also fig. 2) (Renier et al., 1983). The 
behaviour of fra(X) patients has autistic-like features, manifested as avoidance 
of eye contact and/or shyness even to relatives (Goldfine et al., 1985; 
McGillivray et al., 1986; Reiss et al., 1986, Borghgraef et al., 1987; Simko 
et al., 1989). In addition, hyperactivity and a characteristic speech such as 
stuttering and perseveration on words and phrases are striking features of 
these patients (Newell et al., 1983). 
In general, heterozygous females are less severely affected than hemizygous 
males. These females display a broad range of dysfunctions and may be 
mentally normal, mildly affected, or even severely retarded (Kemper et al., 
1986; Loesch and Hay, 1987; Veenema et al., 1987; Reiss et al., 1989; 
Borghgraef et al., 1990; Grigsby et al., 1990; Hagerman et al., 1992). About 
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Fig. 2. Two brothers with the fra(X) syndrome. Note extreme differences of 
facial appearances. 
50% of these females are self-supporting in society (Cronister et al., 1991). 
The majority of fra(X) females also show a decline in IQ scores with 
increasing age similar as seen in male patients (Fisch et al., (1994). 
Cytogenetic Detection of Fra(X) Sites 
In 1969, Lubs found that the presence of a terminal constriction on the 
long arm of the X chromosome appeared to be associated with mental 
retardation (fig. 3). At that time, the importance of the association was not 
fully appreciated, as other laboratories were unable to reproduce his finding. 
In 1977, Sutherland discovered that the cytogenetic appearance of the so-
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Fig. 3. Metaphase preparation of banded chromosomes. Arrow points to the 
fra(X) site on the X chromosome. 
called fra(X) site was highly dependent upon the use of folic-acid deficient 
culture medium. This was followed by numerous reports in the early 1980s in 
which these findings were confirmed, and it was concluded that 30 to 50% of 
mental retardation with X-linked inheritance is indeed associated with the 
presence of the fra(X) chromosome (Herbst, 1980; Jacobs et al., 1980; 
Turner et al., 1980; Venter et al., 1981; Brookwell et al., 1982). However, 
the interpretation of the cytogenetic test results are not always 
straightforward. Even under optimal culture conditions the proportion of 
fra(X)-positive cells in affected individuals does not exceed 50%. Also the 
number of fra(X) sites does not show a positive correlation with the degree of 
the mental handicap. It is well documented now that, while the fra(X) site can 
be detected efficiently in clinically affected individuals, the cytogenetic 
detection rate of the mutation in mentally normal females is very low and 
zero in male carriers (Fryns and Van Den Berghe, 1982; Howard-Peebles and 
Friedman, 1985; Veenema et al., 1987; Smits et al., 1992). 
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Linkage Analysis Using Restriction Fragment 
Length Polymorphisms (RFLPs) 
Since the early eighties, a number of investigators set out to find the 
molecular basis of the fra(X) syndrome. Genetic linkage indicated that the 
causative mutation must be located close to or in the fra(X) site itself. The 
first report of positive linkage with fra(X) associated mental retardation was 
published in 1983 by Filippi et al. using a glucose 6-phosphate dehydrogenase 
protein polymorphism. Camerino et al. (1983) reported the first linkage with 
a DNA marker (pFIX). Subsequent linkage studies in fra(X) families were 
focused mainly on the pFIX marker and a second, highly polymorphic, distal 
marker (pStl4). Although these latter two markers flank the fra(X) disease 
locus (Oberlé et al., 1986; Mulley et al., 1987), they show significant 
recombination with the fra(X) locus (Warren et al., 1985; Brown et al., 
1988), severely limiting their applicability and accuracy in genetic counseling. 
Obviously, more closely linked polymorphic markers were needed in order to 
make accurate carrier detection in fra(X) families feasible. Numerous 
additional markers were mapped within the Xqter region (Brown et al., 1988; 
Dahl et al., 1989; Oostra et al., 1990; Hulsebos et al., 1991; Rousseau et al., 
1991; Suthers et al., 1991; van Oost et al., 1991; Riggins et al., 1992; 
Dreesen et al., 1993). These markers are summarized in figure 4. 
An example of a DNA linkage analysis in a fra(X) family is given in figure 
5. In this family the proximal probe pVK23B (Zz) with a recombination 
fraction of 1% and the distal probe pU6.2 (Ss) with a recombination fraction 
of 3%, were informative for carrier detection. Cytogenetic expression was 
present only in the mentally impaired individuals. In each of them the same 
"z s" haplotype was found. This haplotype was found also in the obligate 
carriers (111:5, IV:2 and IV:4). One further normal male carrier was identified 
(111:8) which implicated that his daughters were also at a high risk for 
carriership (99%). In this branch of the pedigree, linkage analysis revealed 
the presence of a carrier granddaughter (V:7). Prenatal diagnosis after 
chorionic villus sampling (CVS) was performed in 5 cases (IV:4,5,8,9,10) in 
this family using the CA-repeat RS46 (R2,R3), a highly polymorphic marker 
which is located about 150 kbp proximal to the fra(X) locus (Riggins et al., 
1992), see also figure 4. In two of these cases (V:4, V:10) the allele at risk 
(R2) was found. This was confirmed by the cytogenetic observation of fra(X) 
sites in both villi samples and was consistent with the non affected individual 
111:8 being a carrier of the fra(X) mutation. This example illustrates that the 
development of closely linked polymorphic DNA markers has dramatically 
7 
increased the precision of post- and prenatal carrier detection and, as such, 
has contributed significantly to the feasibility of genetic counseling. 
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Fig. 4. Relative location and genetic distances for DNA loci physically and 
genetically mapped within the Xq27-q28 region. 
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Fig. 5. Post- and prenatal carrier detection in a family with DNA probe pVK23B 
(Zz), DNA probe pU6.2 (Ss) and the CA-repeat RS46 (R2.R3). See 
figure 4 for the relative location of these markers. Absence and presence 
of cytogenetic expression is indicated by "-" and " + " , respectively, 
right above pedigree symbols. The linkage phase is indicated by "z+s" 
in which " + " indicates the presence or the inferred presence of the 
fra(X) mutation. The absence or the inferred absence of the fra(X) 
mutation is indicated by "-" in the haplotype notation. Affected 
individuals are designated by solid symbols. Pedigree symbols reduced in 
size represent prenatal tests and solid symbols of this latter group 
indicate the presence of the allele at risk. The probandus is marked by an 
arrow. 
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Cloning of the Fra(X) Locus and 
Carrier Detection Using CGG Repeat Length 
Various techniques have been applied for cloning of the fra(X) locus. 
Vincent et al. (1991) and Bell et al. (1991) used pulsed-field gel 
electrophoresis and found a CpG island which exhibited abnormal methylation 
patterns in fra(X) patients. A YAC (yeast artificial chromosome) containing 
the region with the abnormally methylated CpG island was shown to span the 
fra(X) site by fluorescent in situ hybridization (Vincent et al., 1991). Ober lé 
et al. (1991) and Yu et al. (1991) performed Southern blot analysis using 
subclones adjacent to the CpG island and found evidence for unstable DNA. 
In fra(X) male patients no normal sized restriction fragment was present 
anymore but instead a multitude of different larger fragments were seen, 
presenting as a "smear". In normal transmitting males (NTMs) a small 
insertion (50 to 500 base pairs (bp)) was found. 
Warren et al. (1987, 1990) generated a set of somatic cell hybrids via fusion 
of Chinese hamster ovary cells with lymphoblasts from a male patient with 
the fra(X) syndrome. After induction of fra(X) expression, hybrids were 
selected containing either the region proximal or the region distal to the 
fra(X) locus translocated to a hamster chromosome. These somatic cell 
hybrids appeared to be essential for subsequent mapping and cloning studies. 
Verkerk et al. (1991) identified a YAC which spanned the breakpoint in two 
reciprocal translocation hybrids. With a four-cosmid contig derived from this 
YAC, it was found that most of the breakpoints occurring in Warren's 
hybrids were clustered within a 5.1 kb EcoRI fragment. In this region also an 
abnormally methylated CpG island was found in fra(X) patients. These 
cosmids were, subsequently, used to isolate from a fetal brain cDNA library a 
cDNA corresponding to a gene that was designated FMR1 (fragile X mental 
retardation gene 1). In the 5' end of the first exon of the FMR1 gene a 
sequence was identified containing a CGG trinucleotide repeat. The 
previously mentioned "smears" appeared to be due to large expansions of the 
CGG triplet repeat. 
More precise analysis of this repeat among normal individuals demonstrated 
frequent length polymorphisms, ranging from 6 to 50 repeats (fig. 6) (Kremer 
et al., 1991: Fu et al., 1991). In individuals with the fra(X) mutation the 
expanded CGG repeat can be classified in two main types (fig. 6). 
(i) In nonpenetrant fra(X) carriers a restriction fragment length increase of 
150 to 600 bp, corresponding to 50 to 200 CGG trinucleotide repeats, is 
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Fig. 6. Amplification of the CGG repeat leads to two main types of fra(X) 
mutations: a small insertion (premutation of 50-200) which does not 
cause mental retardation and a large insertion (full mutation of more than 
200 triplets) with a high risk of mental retardation. In the normal 
population the repeat length varies between 6-50 (bottom part of the 
triangle). 
found, which is termed a premutation sized allele. This fragment, next to a 
normal-sized fragment, is seen in daughters of NTMs. When a female carrier 
passes on her premutation chromosome the CGG repeat behaves extremely 
unstable and may undergo an increase in size to a full mutation (Fu et al., 
1991; Oberlé et al., 1991; Heitz et al., 1992; Mulley et al., 1992; Yu et al., 
1992). (ii) The full fra(X) mutation, which is characterized by a dramatic 
amplification of the number of CGG triplet repeats far beyond 200. This 
increase is somatically unstable and generates a multitude of restriction 
fragments ("smear") and leads to the characteristic phenotype of the fra(X) 
syndrome in males. On the other hand, female carriers of the full mutation 
may be either normal functioning or mentally affected (Rousseau et al., 1991; 
Mulley et al., 1992; Smits et al., 1992; Yu et al., 1992). 
Scope of the Thesis 
The objective of the studies described in this thesis was to gain insight 
into the enigmatic inheritance pattern of one of the most prevalent X-linked 
disorders associated with mental retardation: the fragile X (fra(X)) syndrome 
(fragile Xq27.3). 
After an historical introduction in chapter 1, studies on the origin of the 
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fra(X) mutation within families are reported in chapters 2 and 3. The data 
indicate that the mutation rate for the fra(X) syndrome is low. 
Incomplete penetrance of the fra(X) mutation occurring in females as well as 
in males, has important implications for genetic counseling and is the topic of 
the following three chapters. Chapter 4 describes a refinement of the 
estimates of these penetrances, in particular with regard to the parental origin 
of the fra(X) mutation, the mental status of the carrier mother and the 
presence of a NTM in a given family. In chapter 5 the direct estimate of the 
penetrance of the fra(X) mutation is compared with the estimate using a 
computer program based on the inheritance characteristics of sex-linked 
diseases. In chapter 6, the effect of the parental origin of the fra(X) mutation 
on both the cytogenetic expression and the CGG repeat length is reported. 
At present, carrier detection for the fra(X) syndrome is carried out by direct 
detection of the CGG repeat. In order to evaluate the usefulness of this 
diagnostic test a validation is presented in chapter 7. In chapter 8, the 
sensitivity, specificity and predictive value of CGG repeat analysis is reported 
and discussed in relation to adequate genetic counseling in fra(X) families. 
Chapter 9 describes a detailed study of a familial case with a full mutation in 
brothers without any clinical consequences. This exceptional family enabled 
us to assess relationships between CGG repeat length and methylation status 
of the 5' end of the FMR1 gene, the transcription of the gene, the ultimate 
FMR1 protein level, the cytogenetic fragile site expression and the clinical 
status. 
Finally, in chapter 10, issues concerning carrier detection in high risk 
populations, in particular fra(X) families, are discussed. 
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SUMMARY 
The overall prevalence of the fragile X (fra(X)) mutation, as determined 
by population studies, is approximately 1 in 850 (Gustavson et al., 1986; 
Webb et al., 1986). This prevalence suggests a very high mutation rate 
which, in turn, suggests that many patients have to represent sporadic cases. 
In order to obtain an accurate estimate of the proportion of sporadic cases, we 
performed genealogie, cytogenetic and DNA linkage studies as well as direct 
analysis of the CGG repeat in relatives of 84 fra(X) probands. We did not 
find any evidence for the presence of sporadic cases. In 11 probands 
consanguinity could be proven by the detection of common ancestors, in 5 
related families up to 9 generations ago. In the other 6 related families the 
mutation could be traced back 4-6 generations. In 3 or more generation 
families we were able to demonstrate that half of the probands carried the 
grandpaternal fra(X) gene. These results imply that rather than a high 
mutation rate, both Normal Transmitting Males (NTM's) and mentally normal 
female carriers contribute considerably to the high prevalence of the fra(X) 
syndrome. 
INTRODUCTION 
The fragile X (fra(X)) syndrome, the most common cause of familial 
mental retardation, is an X-linked disorder which co-segregates with a fragile 
site at Xq27.3 (Lubs, 1969; Sutherland and Hecht, 1985). Population surveys 
in Sweden and England (Gustavson et al., 1986; Webb et al., 1986) have 
demonstrated that the prevalence of affected males is approximately 1/1250, 
whereas that of affected females is 1/2000. Sherman et al. (1984, 1985) 
estimated a penetrance of the mutation in males and females of 79% and 
35%, respectively, which led to the prediction that the fra(X) gene frequency 
would be 1/850. 
Since the reproductive fitness of affected males and females is reduced, the 
fra(X) gene should gradually be lost from the gene pool. In order to 
compensate for this loss, a high mutation rate has been suggested (Froster-
Iskenius et al., 1984; Sherman et al., 1984, 1985; Brown, 1990). When 
assuming equal mutation rates in egg and sperm, approximately 37% of the 
affected males are expected to be the result of a new mutation (Sherman et 
al., 1988). 
In order to obtain a more accurate estimate of the proportion of sporadic 
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cases (i.e. new mutations), we performed genealogie, DNA linkage and 
cytogenetic studies in conjunction with direct DNA analyses of the CGG 
repeat in the relatives of 84 fra(X) probands. 
MATERIALS AND METHODS 
Family Studies 
In this study all available ancestors of 80 fra(X) male probands and 4 
female probands were included. Diagnosis of the fra(X) syndrome in the 
probands was based on cytogenetic expression of the fragile site at Xq27.3. 
Once diagnosed, the subsequent standard procedure was to contact relatives of 
every proband and visit them at home to collect complete anamnestic 
information. Based on this information more distant relatives were contacted. 
In order to trace common ancestors, genealogie data up to the middle of the 
eighteenth century were collected from local archives. 
Cytogenetic Analysis 
Blood samples from probands and relatives were cultured in medium 199 
(which is low in thymidine and folic acid), supplemented with 5% fetal calf 
serum. Hundred metaphases of each individual were examined for the 
presence of a fra(X) chromosome after solid Giemsa staining. Putative fra(X) 
chromosomes were destained and GTG-banded for confirmation. 
DNA Analysis 
Polymorphic restriction enzyme site and CA repeat typing for loci closely 
linked to the fragile site were performed in the genetic workup of 38 families 
in which the fta(X) syndrome is segregating (Oostra et al., 1990; van Oost et 
al., 1991, 1992; Riggens et al., 1992). Direct detection of the fra(X) mutation 
was performed by Southern blot analysis of Pstl-digested DNA of 25 fra(X)-
positive probands, their mothers and 14 grandparents. Blots were hybridized 
with pA0365, a 600 bp Xhol-PstI fragment derived just 3' from the CGG 
repeat (Verkerk et al., 1991). The PstI fragments sizes were classified as 
follows (van Oost et al., 1992): (i) uniform fragment of normal length and 
normal intensity (1.0 kbp fragment), (ii) uniform fragment of increased length 
and a single dosis intensity, (iii) multiple recognizable bands of reduced 
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intensity identified by the fragment size from which the smear developed 
upwards, (iiii) complete absence of a hybridization signal with an apparently 
normal amount of DNA present in the lane. 
RESULTS 
Anamnestic Analysis of Fra(X) Families 
In order to obtain an accurate estimate of the proportion of sporadic 
cases, all 84 fra(X) probands and their relatives known to us were included. 
From anamnestic information it became clear that 41 probands had at least 
one affected sib as well as a more distant affected relative. In 16 probands 
with mentally normal sibs, the fra(X) syndrome was manifest in one or more 
distant relatives. Likewise, 19 probands had only one or more affected sibs in 
the absence of more distant affected relatives. In 8 of the remaining proband 
families, the family history was unremarkable. Anamnestic information of 3 
proband families of this latter group was hard to obtain, as the parents had 
left the country or were not cooperative. 
Genealogical Analysis of Fra(X) Families 
Genealogical data were used to find relationships between the probands, 
and to trace back the mutation. In a total of 11 probands consanguinity could 
be demonstrated. The common ancestors of 5 probands were traced back to 
the early 18th century. Two probands were related up to 6 generations ago 
and for 2 pairs of probands common ancestors were found after ascending 4-5 
generations. 
Amplification of a CGG Repeat Sequence was 
Found in all Presumed Carriers 
Direct detection of the fra(X) gene was performed via the analysis of the 
CGG repeat length in 25 affected male probands, their mothers and available 
grandparents (Table I). 
All tested probands, including the 5 isolated fra(X) patients and their mothers 
as well as all 14 tested grandparents could be identified as gene carrier as 
they demonstrated the typical size increase and/or dispersion of the CGG 
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repeat containing PstI fragment. Four of the 7 mothers showed a minor 
dispersion (defined smear) of the CGG repeat. The fragment size from which 
the dispersion developed upwards was 1.3-1.6 kb. In contrast to these 
mentally normal carrier mothers, a full mutation was found in three mentally 
impaired mothers. Two of the latter group showed a dispersion of the CGG 
repeat which developed upwards from 1.7 kb and 2.0 kb, respectively, and 1 
TABLE I. Distribution of CGG Repeat Length for Fra(X) Male 
Probands, Their Mothers and Grandparents. 
CGG Repeat Length in Kb (PstI fragment) 
Proband 
Mother 
Grandmother 
Grandfather 
Total 
Normal3 
fragment 
0 
0 
0 
0 
0 
Increased 
fragment 
0 
18 
6 
7 
31 
Defined0 
smear 
18 
6 
1 
0 
25 
Absenced 
signal 
7 
1 
0 
0 
8 
Total 
25 
25 
7 
7 
64 
a: Uniform fragment of normal length and normal intensity (1.0 kbp). 
b: Uniform fragment of increased length and single-dose intensity, ranging in size 
from 1.2-1.6 kbp. 
c: Multiple recognizable bands of reduced intensity identified by the fragment size 
from which the smear developed upwards. The fragment size from which the 
smear developed was 1.4-4.7 kbp. 
d: Complete absence of hybridization signal with an apparently normal amount of 
DNA present in the lane. 
mother showed complete absence of hybridization signal. All the affected 
probands (n=25) carried the full mutation, since a dispersion with an increase 
in size of 700 to 3700 bp or complete absence of hybridization signal was 
observed. 
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Thus, carriership of the fra(X) mutation could readily be detected directly in 
all available mothers and ancestors of the probands and in many cases also 
indirectly by using anamnestic information (Table II). In those pedigrees 
(n=49) in which we were able to trace back the mutation to the grandfather 
or grandmother of the proband, grandpaternal inheritance of the fra(X) gene 
could be demonstrated for 25 cases. 
TABLE Π. Number of Generations in Which the Fra(X) Mutation was 
Found in Different Proband Families. 
Number of generations* Number of probands 
5 10 
4 16 
3 19 
2 20 
la 5 
Total 70 
* Probands were accounted as generation 1 
a For these families carriership of the mother was only proven by CGG repeat 
analysis. 
Expansion of the CGG Repeat Through Generations is not Obligatory 
We studied the change in mutation patterns after passage through a 
Normal Transmitting Male (NTM) and their carrier daughters (Table III). As 
a general rule, the premutation is transmitted by a NTM to his daughter and 
changed to a full mutation during oogenesis. However, daughters of a NTM 
do not show in every instance an increased fragment length similar to that 
found in their carrier father. Small variations of the fragment, both increased 
(50-300 bp) and decreased (50-150 bp) in size, were encountered. However, 
we did not observe any full blown mutation in women carrying the paternal 
fra(X) mutation. In contrast, a full mutation was found in all but three 
mutation-bearing grandchildren of NTM's (n=29). Nineteen of the latter 
group showed multiple recognizable bands of reduced intensity, whereas the 
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TABLE Ш. Inheritance of PstI Fragment Length (CGG repeat) 
Psü Fragment Length 
Family 
Grandfather Daughters Carrier grandsons Carrier granddaughters 
Affected Normal Affected Normal 
I 
π 
Ш 
Г 
V 
VI 
П 
Ш 
EX 
X 
0.2 
0.4 
0.2 
0.35 
0.5 
0.4 
0.4 
0.4 
0.3 
0.3 
S 
s 
s 
s 
s 
0.4 
0.5 
0.5 
0.3 
0.3 
0.5 
0.5 
0.4 
0.3 
0.4 
0.25 
0.35 
0.4 
0.4 
0.3 
0.3 
0.5 
(2) 
(6) 
(2) 
(2) 
(2) 
S 
S 
S 
S 
s 
s 
s 
s 
s 
s 
s 
s 
s 
2.0 
7 
4.0 (2) 
5.5 (2) 
8.0 
? (3) 
2.0 
1.5 
-
3.8 
2.0 
-
2.5 
? 
1.8 
XI 0.3 0.3 S 1.8 
S 1.4 0.2 (2) 
S 1.5 
S ? (5) 
S 1.2 
S 2.0 
S 3.8 
S 2.4 
0.4 
S : Multiple recognizable bands of reduced intensity as identified by an increased 
fragment size. 
S ? : Complete absence of hybridization signal with an apparently normal amount 
of DNA present in the lane. 
( ) : Number of individuals. 
- : Not present. 
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remaining subjects (η =10) exhibited complete absence of a hybridization 
signal. In 3 mentally normal granddaughters, the grandpaternal premutation 
appeared to be unchanged. The CGG repeat analysis was in all cases 
consistent with the probabilistic diagnosis based on linked DNA markers (van 
Oost et al., 1992). In Fig. 1 the maternal transmission of the fra(X) mutation, 
over 3 generations is illustrated. 
IV 
01 
D-
3 
-O 
ND 
2 1 
* -
Δ 0.3 
3 2 
- * 
3 
-ns- * r 
_ _ 3 
o-
Δ 0 . 3 
2 2 
* -
645 
Δ 0.4 
2 3 
* -
4 
-D 
Δ S >0.7 
2 3 
* -
Δ S >3.5 
/ 2 3 
A S >3.7 A S > 3 . 7 A S >1.0 
/ 2 2 2 
/ * * * 
Fig.l. Pedigree of a fra(X) family. The fra(X) mutation is segregating over 4 
generations through the maternal line. The * denotes the fra(X) disease 
locus. The numbers 1,2,3 represents the alleles of the DXS548 locus seen 
in this family. The fra(X) gene co-segregates with allele "2". ¿s refers to 
the increase in size (in kilo base pairs) of the CGG repeat, after PstI 
digestion. Bar over symbol denotes a cytogenetically negative test, hatched 
symbol denotes fra(X) positive and mentally normal, solid symbols denote 
mentally retarded subjects with fra(X) expression. Arrows indicate 
propositi. ND: CGG repeat analysis not done. 
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The premutation was introduced into the family by a phenotypically normal 
female (1-2), who transmitted the mutation to her mentally normal daughters 
(II-1 and II-2). The available relatives were typed by cytogenetic and DNA-
linkage analyses, using the polymorphic DNA marker DXS548 (2), and by 
direct DNA diagnosis after PstI cleavage. The fra(X) gene in this family co-
segregated with allele 2 of the DXS548 locus. Both granddaughters were 
fra(X) chromosome negative, and Southern blot analysis of Subject III-3 
showed an increase in PstI fragment length of 300 bp. The great-
granddaughters (IV-1, IV-3, and IV-5) also did not express any clinical 
symptom of the mutation. However, while 2 of these great-granddaughters 
were cytogenetically negative and carried a defmed increased fragment in the 
normal transmitting range, the other great-granddaughter (Г -5) was 
cytogenetically positive (7%) and the CGG repeat was dispersed. In the fifth 
generation, each individual had a strong increase in fragment size ranging 
from 1000 to 3700 bp. 
Cytogenetic Analysis is Inadequate for Carrier Detection 
A total of 37 mothers of the male probands was tested cytogenetically and 
7 demonstrated the fra(X) chromosome in 0.5% to 20% of the cells. Three of 
the 7 mothers appeared to be mentally impaired. The father of one female 
proband was also cytogenetically tested but was found to be negative. Only 2 
of the 23 cytogenetically tested grandmothers of the probands were fra(X) 
positive, 1.5% and 7% respectively, and none of the 13 cytogenetically tested 
grandfathers, which indicates that cytogenetic analysis is inadequate for 
carrier detection. 
DISCUSSION 
In this study we have shown that in all our informative fra(X) families 
(n=81) the mutation is familial. This result is based on anamnestic 
information, supported by cytogenetic and DNA-linkage analyses as well as 
direct detection of the CGG repeat. In addition, extensive genealogical 
studies, which we performed in order to find common ancestors of the 
probands, indicate that the fra(X) mutation might find its origin even more 
than 270 years ago. Analysis of linkage disequilibrium with the closely linked 
DXS548 locus in these large families lends further support to this notion 
(Smits et al., in preparation). Jacobs et al. (1986) reported a dearth of 
isolated cases of affected males and females in 270 analysed pedigrees. In 
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addition, results of direct DNA diagnosis in 63 fra(X) families, published 
recently by Rousseau et al. (1991), showed a lack of evidence for new 
mutations and the authors concluded that all mothers of affected males and 
females were carriers of either a premutation or a full mutation. Sherman et 
al. (1988) reported that about a quarter of all fra(X) probands resulted from 
new mutations, i.e. were sporadic cases. Even if one assumes that the 
mutation might develop through several méioses, this seems to be an 
overestimate because, up to now, we failed to find a new mutation in all 
tested parents of persons with a premutation. 
Several hypotheses have been proposed to explain the development of the 
fra(X) syndrome (Pembrey et al., 1985; Nussbaum et al., 1986; Laird et al., 
1987). The common denominator of these hypotheses is a two-step process. 
The first step implies the transmission of the premutation to a female, which 
then has to be passed through oogenesis. In this oogenetic step, the 
premutation is converted to a full mutation. Our data from families with a 
male transmitter appear to be consistent with this two- step model, at least as 
far as most of the carrier grandchildren is concerned. Analysis of families in 
which the fra(X) syndrome is segregating has shown general patterns of size 
variation for the CGG repeat unit. NTM's and their daughters show only a 
small increase of the CGG repeat, while fra(X)-positive individuals in the 
next generation exhibit much larger fragments that may differ among siblings. 
These results are in accordance with data, recently published by Oberlé et al. 
(1991). Thus increase of the CGG repeat length is not obligatory by passage 
of the premutation through a male and his daughter. The premutation may 
still be present in grandchildren with grandmaternal transmission of the fra(X) 
mutation (see Fig.l). These observations confirm results published by 
Holmgren et al. (1988) concerning large fra(X) families in which the mutation 
resulted in clinical manifestation of the fra(X) syndrome only after several 
generations. It can be anticipated that non manifesting carriers with the 
maternal as well as with the paternal inherited mutation contributes to a large 
extent to the fra(X) gene pool. This assumption is strengthened by the 
observation that half of our probands inherited the mutation from their 
mentally normal grandfathers. 
Vogel (1984) reported that an increased fertility of mentally borderline 
females might contribute to the high incidence of the fra(X) mutation. In our 
analysis we found no evidence for such an increased fertility among affected 
female carriers with children (Wilcoxon, Ρ >0.45). On the contrary, the 
highest number of children was born to carrier females of normal 
intelligence. However, the number of children of this latter group has as yet 
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not been compared to a control group. 
In conclusion, we did not find any evidence for the presence of sporadic 
cases, which indicates that the new mutation rate must be negligible, or more 
likely that the mutation originates by a gradual multigenerational process. 
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SUMMARY 
Fragile X (fra(X)) syndrome, the most common forni of familial mental 
retardation, is caused by heritable unstable DNA composed of CGG repeats. 
As reproductive fitness of fra(X) patients is severely compromised, a high 
mutation rate has been proposed to explain the high prevalence. However, we 
have been unable to show any new mutation for 84 probands referred to us to 
date. We show here the same fra(X) gene in five fra(X) probands with 
common ancestors married in 1747. The lack of new fra(X) mutations implies 
that there must be many more fra(X) gene carriers in the population than 
previously realized. As it is now possible to detect asymptomatic fra(X) gene 
carriers by DNA analysis, extended family studies for any new proband are 
recommended. A family illustrating the importance of fra(X) carriership 
determination is reported. 
INTRODUCTION 
The fra(X) syndrome is the most common form of familial mental 
retardation. Owing to the severity of the disorder, reproductive fitness is 
greatly diminished in nearly all affected males as well as in a significant 
proportion of female patients. Therefore, a high mutation rate has been 
invoked to account for its high prevalence. However, as noted by Jacobs et 
al., (1986), there appears to be a dearth of new mutations. During the follow 
up of our 84 index patients, even after going back many generations, we have 
failed to detect any new mutations (Smits et al., 1992). Similarly, in two 
other extensive surveys, no new mutations could be found (Rousseau et al., 
1991; Yu et al., 1992). An alternative explanation for the lack of new 
mutations might be recurrent new mutations in the same pedigree. We could 
discount this latter possibility by showing linkage disequilibrium in a large 
fra(X) pedigree between the fra(X) gene and a closely linked polymorphic 
DNA marker. Thus, the fra(X) gene may be transmitted for many generations 
before becoming manifest. The realization that new fra(X) mutations are very 
rare has far reaching implications for the counselling of (distant) relatives of 
fra(X) probands. 
MATERIALS AND METHODS 
Fra(X) probands were ascertained as described previously (Smits et al., 
1992). Genealogical studies were based on municipal documents and 
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information from the families. DNA extracted from patients' blood samples 
was analyzed for restriction fragment length polymorphisms, the CA 
dinucleotide repeat polymorphism at the DXS548 locus, and for the CGG 
repeat in the FMR-1 gene (Smits et al., 1992; Smits et al., 1992; Verkerk et 
al., 1991). The length of the CGG repeat in the normal range was also 
analyzed by PCR (Fu et al., 1991). 
RESULTS AND DISCUSSION 
Segregation Analysis in a Large Fra(X) Family 
Five fra(X) probands with common ancestors in the early 18th century 
were ascertained in two different clinical genetics centers in The Netherlands. 
In all families there were two or more patients displaying the Martin-Bell 
phenotype and the chromosomal fragile site at Xq27.3. In two probands the 
fra(X) mutation was inherited from the maternal grandmother and in three 
probands the maternal grandfather had passed on the fra(X) mutation (fig.l). 
The highly polymorphic DXS548 locus is located 140.000 bp proximal to the 
fra(X) gene locus on the X chromosome (Riggens et al., 1992). DXS548 can 
be characterized by PCR analysis of the variable number of CA dinucleotide 
repeats at this locus. In agreement with our previous studies in a cohort of 
normal subjects and fra(X) patients from the United States (Riggens et al., 
1992), there is no apparent linkage disequilibrium between the DXS548 
marker and the fra(X) locus (see fig.l for a subset of unrelated fra(X) patients 
from The Netherlands). However, when the five related probands were tested 
all showed exactly the same allele of 202 bp (fig.l). As this allele has a 
frequency of 15% in the population, the chances are less than 1 in 2000 that 
this result is fortuitous. It is obvious from the pedigree that the fra(X) gene 
can apparently pass through a number of male and female méioses before 
becoming manifest. The fra(X) gene has been found to be a segment of 
unstable DNA (Oberlé et al., 1991; Yu et al., 1991) caused by the expansion 
of a CGG trinucleotide repeat sequence in the 5' end of the FMR-1 gene 
(Verkerk et al., 1991). Normal subjects have between six and 46 copies of 
the repeat, while asymptomatic gene carriers may have 52 to over 200 copies 
of this repeat (Fu et al., 1991). Fra(X) patients are mosaics in which the 
repeat might be expanded up to thousands of repeats. Male transmission of 
the gene is not accompanied by large changes in repeat size, but in female 
méioses the repeat usually expands. However, this is not obligatory (Rousseau 
et al., 1991; Yu et al., 1992). It has been hypothesized by Sutherland et al., 
(1991) and shown by Fu et al., (1991) that it is this plasticity of the fra(X) 
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Fig. 1. The polymorphic marker DXS548 is in linkage disequilibrium with the 
fra(X) gene in an extended pedigree. Analysis of the CA repeat 
polymorphism at the DXS548 locus in seven unrelated fra(X) patients (lanes 
1-7) and in five fra(X) probands with common ancestors married in 1747 
(lanes 9-12). With specific primers flanking the polymorphic CA repeat, a 
DNA fragment of 192 to 210 bp was synthesised by the polymerase chain 
reaction (Fu et al., 1991). The fragments were resolved on a 6% Poly­
acrylamide gel. By labelling one of the primers with31 Ρ the fragments 
could be visualized by autoradiography. 
mutation that explains its variable clinical expression and its unusual genetics. 
Morton et al., (1992) have developed a model in which it is postulated that 
the expansion of the CGG repeat arises only on X chromosomes which have a 
larger than normal, but stable, CGG repeat. These alleles may be quite 
common and only when they increase further in length can the fra(X) 
syndrome develop in the next generations via female méioses. This model 
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might also explain the inheritance seen in our pedigree in that the fra(X) has 
been transmitted many times without significant enough expansion to impede 
reproduction. Recently, Richards et al., (1992) noted remarkable linkage 
disequilibrium between the fra(X) locus and two very closely linked CA 
repeats. The family presented here provides the basis for what these 
investigators observed in mostly Caucasian populations in the United States 
and Australia where only a few generations were traced. 
DNA Analysis in a Family with an Apparently Isolated Fra(X) Case 
The apparent lack of new mutations brings into question whether many 
more gene carriers might be identified through repeat analysis in any family. 
That this is likely to be the case is exemplified by our recent analysis of a 
family with a single patient (fig.2). Subject 1, a cousin of the patient (subject 
11), wanted to know her carrier status before becoming pregnant. Linkage 
analysis with the closely linked flanking DNA markers indicated that the 
proband had inherited the grandpaternal X chromosome (fig.2, panel A). 
Direct analysis of the CGG repeat length by Southern blotting (fig.2, panel B) 
and PCR analysis (fig.2, panel C) showed in all daughters in the second 
generation an increased fragment of 200 bp, characteristic of the premutation 
in the fra(X) syndrome. This indicated that the grandfather must have been a 
'normal transmitting male'. In the affected grandson (subject 11) a greatly 
expanded repeat of about 3000 bp in length was seen, while in his 
phenotypically normal cousin (subject 2), who had also inherited the 
grandpaternal X chromosome, a less pronounced expansion of the CGG 
repeat of 500 bp was seen. Of the females in this family, only the 
grandmother and the consultant did not carry the fra(X) gene. 
CONCLUSION 
The origin of the fra(X) mutation in the families described here as well as 
in virtually all other fra(X) families remains elusive. Neither has the 
conversion of a normal allele to a non-phenotypic premutation allele or to a 
full mutation been reported. However, the observation that the fra(X) 
chromosomes of different fra(X) families carry different alleles at the DXS548 
locus makes it unlikely that new mutations do not occur. Indeed, there is no a 
priori argument in favor of the absence of new mutations. It may take an as 
yet undetermined number of generations before the fra(X) mutation surfaces. 
In view of this latency of the fra(X) mutation, quite distant relatives of any 
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Fig. 2. DNA linkage and direct mutation analysis in a family with a single 
fra(X) patient. Analysis of the polymorphic DNA markers DXS539 (Hh), 
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DXS466 (Gg), and DXS304 (Ss) (upper panel A), and direct analysis of 
the CGG repeat by Southern blotting of PstI digests of the patient's 
genomic DNA (middle panel B), and by PCR with primers flanking the 
CGG repeat (lower panel C). In the pedigree the at risk allele is 
indicated by an asterisk. For subject 13, the Southern blot is not 
unequivocal as the signal of the normal X chromosome is not clearly 
distinguishable. This can be explained by the fact that this subject 
inherited the maternal X chromosome with the larger, but still normal, 
CGG repeat from her mother, the same allele as her two brothers 
(subjects 6 and 8). Owing to the inefficiency of the PCR for longer CGG 
inserts, the product of the expanded alleles in the gene carriers could not 
be shown. Only the consultant and her grandmother show heterozygosity 
for the normal sized alleles of the CGG repeat, confirming their non-
carriership. 
fra(X) proband may be at risk for fra(X). Therefore, our data suggest that 
carrier detection by DNA analysis is indicated throughout extended families 
identified through new probands, and that population based screening may be 
warranted. 
REFERENCES 
Fu YH, Kühl DPA, Pizutti A (1991): Variation of the CGG repeat at the 
fragile X site results in genetic instability: resolution of the Sherman paradox. 
Cell 67:1047-1058. 
Jacobs PA, Sherman SL, Turner G, Webb Τ (1986): The fragile X syndrome: 
the mutation problem. Am J Med Genet 23:611-617. 
Morton NE, Macpherson JN (1992): Population genetics of the fragile X 
syndrome: multiallelic model for the FMR-1 locus. Proc Natl Acad Sci USA 
89:4215-4217. 
Oberlé I, Rousseau F, Heitz D (1991): Instability of a 550-base pair DNA 
segment and abnormal methylation in fragile X syndrome. Science 252:1097-
1102. 
Richards RI, Holman К, Friend К (1992): Evidence of founder chromosomes 
in fragile X syndrome. Nature Genet 1:257-260. 
Riggins GJ, Sherman SL, Oostra В A (1992): Characterization of a highly 
polymorphic dinucleotide repeat 150 kb proximal to the fragile X site. Am J 
Med Genet 43:237-243. 
Rousseau F, Heitz D, Biancalana V (1991): Direct diagnosis by DNA analysis of 
the fragile X syndrome of mental retardation. N Engl J Med 325:1673-1681. 
Smits APT, Smeets DFCM, Hamel BCJ, Dreesen JCFM, van Oost BA 
40 
(1992): The high prevalence of the fra(X) syndrome cannot be explained by a 
high mutation rate. Am J Med Genet 43:345-352. 
Smits APT, van Oost BA, de Haan AFJ, Hamel BCJ, Dreesen JCFM, Smeets 
DFCM (1992): Penetrance of fragile X gene: influence of grandparental origin 
of the gene, mental status of the carrier mother, and presence of a normal 
transmitting male. Am J Med Genet 43:365-372. 
Sutherland GR, Haan EA, Kremer E (1991): Hereditary unstable DNA: a 
new explanation for some old genetic questions? Lancet 338:289-292. 
Verkerk AJMH, Pieretti M, Sutcliffe JS (1991): Identification of a gene 
(FMR-1) containing a CGG repeat coincident with a breakpoint cluster region 
exhibiting length variation in fragile X syndrome. Cell 65:905-914. 
Yu S, Pritchard M, Kremer E (1991): Fragile X genotype characterized by an 
unstable region of DNA. Science 252:1179-1181. 
Yu S, Mulley J, Loesch D (1992): Fragile X syndrome: unique genetics of 
the heritable unstable element. Am J Hum Genet 50:968-980. 
41 

CHAPTER 4 
PENETRANCE OF FRA(X) GENE: INFLUENCE OF 
GRANDPARENTAL ORIGIN OF THE GENE, 
MENTAL STATUS OF THE CARRIER 
MOTHER, AND PRESENCE OF A 
NORMAL TRANSMITTING 
MALE 
Arie FT Smits, Bernard A van Oost, Anton FJ de Haan, Ben CJ Hamel, 
Jos CFM Dreesen and Dominique FCM Smeets 
Department of Human Genetics (A.S., B.v.O., В.Н., J.D., D.S.) and 
Medical Statistics (A.d.H.) University Hospital Nijmegen, The Netherlands 
Published in: 
American Journal of Medical Genetics (1992) 43:365-372 

SUMMARY 
Previous studies have indicated that the fragile X (fra(X)) gene does not 
show full penetrance (mental impairment) in carrier females or "carrier" 
males. The phenomenon of non-expressing carrier males distinguishes the 
fra(X) syndrome from all other known X-linked disorders. Moreover, 
penetrance of the fra(X) gene apparently does not show random distribution 
within fra(X) families, but seems to be reduced in sibs of normal transmitting 
males (NTM's). The availability of many large multi-generation fta(X) fami-
lies, studied by cytogenetic and DNA analyses, enabled us to refine the 
estimates of the penetrance. From our data we conclude that the penetrance 
in daughters of carrier females is determined by the mental status of the 
mother. In sons of carrier females, the observed penetrance appears to be 
influenced by the grandparental origin of the gene as well as by the mental 
status of the mother. However, in contrast with the average penetrance, we 
observed a strongly reduced penetrance of the fra(X) gene in brothers (14%) 
and sisters (21%) of NTM's. These findings have profound implications for 
genetic counseling. 
INTRODUCTION 
Since preliminary investigations in our fta(X) families pointed to a much 
higher penetrance (mental impairment) in females than reported thus far, we 
decided to study systematically the penetrance of the fra(X) gene. We were 
able to perform extensive family studies in 77 multi-generation pedigrees. 
Based on these data, including genealogie and cytogenetic results supported 
by DNA linkage studies and direct molecular analysis of the fra(X) mutation 
(Oostra et al., 1990; van Oost et al., 1991; 1992; Smits et al., 1992a), we 
present a refinement of the estimated fra(X) penetrance in the offspring of 
carrier females. The large number of multi-generation families allowed us to 
calculate different penetrance figures with regard to the mental status and the 
parental origin of the fra(X) gene in the carrier mother. In addition, the 
penetrance in brothers and sisters of normal transmitting males (NTM's) 
could be established. The results have direct implications for genetic 
counseling of fra(X) families. 
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MATERIALS AND METHODS 
Family Studies 
The index patients were referred to us for cytogenetic analysis of the 
fra(X) chromosome by clinical residents in public hospitals and institutions 
for the mentally retarded. The standard procedure was to contact the family 
after the fra(X) syndrome had been diagnosed in the proband. Relatives were 
all visited at home, where a detailed family history was taken and the 
intellectual level of the relatives was assessed. All at-risk relatives who 
consented were tested cytogenetically and, if necessary, also at the DNA 
level. Obligate carrier mothers were classified according to their mental 
status. Two levels could be differentiated, normal and borderline. Normal 
mental status implied that no obvious signs of mental disability were present. 
"Borderline females" were mildly affected as they had significant learning 
disabilities, but were self-supporting in society. The mental status of children 
of obligate carrier mothers was obtained anamnestically. All children who 
were learning-disabled according to school criteria and received special 
education were classified as mentally impaired. 
Cytogenetic Analysis 
Blood samples of all individuals were cultured for 96 hours in medium 
199 supplemented with 5% fetal calf serum. One hundred metaphases of each 
individual were examined for the presence of a fra(X) chromosome after solid 
Giemsa staining. Putative fra(X) chromosomes were destained and GTG-
banded for confirmation. 
DNA Analysis 
DNA-linkage analysis and direct detection of the CGG repeat length were 
performed in relatives to diagnose carriers and to trace back the origin of the 
fra(X) gene. The analyses were carried out as described in the accompanying 
paper (van Oost et al., 1992). 
Six polymorphic DNA probes used, Stl4 (DXS52) and U6.2 (DXS304) as 
distal markers, and RN1 (DXS369), JH89 (DXS539), VK23B (DXS297), 55E 
(DXS105) as proximal markers. In addition, we applied a highly polymorphic 
dinucleotide repeat, RS46 (DXS548), which is tightly linked to the fra(X) 
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syndrome locus (Riggins et al., 1992). 
Direct detection of the CGG repeat length was assessed via Southern blot 
analysis of Pstl-digested total genomic DNA. The blots were hybridized with 
a 600 bp Xhol-PstI fragment just 3' from the CGG repeat sequence (Verkerk 
et al., 1991). The PstI fragment sizes were classified as follows: (i) uniform 
fragment of normal length and normal intensity (1.0 kbp fragment), (ii) 
uniform fragment of increased length and a single dosis intensity, (iii) 
multiple recognizable bands of reduced intensity identified by the fragment 
size from which the smear developed upwards, (iiii) complete absence of a 
hybridization signal with an apparently normal amount of DNA present in the 
lanes. 
Segregation Analysis 
Direct estimate of the penetrances was performed by taking twice the 
relative frequency of affected sons and daughters. The numbers of observed 
mentally impaired sons and daughters were evaluated with all possible 
penetrances (0.0-1.0) using a Chi-square test. A 95% confidence limit gives 
an interval estimate for the mean of the penetrance. 
RESULTS 
Since the time that fra(X) studies in our laboratory were initiated, we 
have detected the fra(X) gene in 77 multi-generation families. In these 
families we were able to identify more than 200 carrier mothers. After 
ascertainment correction, by omitting index families (proband, sibs and 
parents) completely, a total of 100 nuclear families, including 347 children 
with defined phenotypes, were subjected to penetrance analysis. Estimation of 
the penetrance in sibs of NTM's was performed in 21 families in which a 
NTM was identified. Ascertainment correction was applied by excluding the 
index NTM's, leaving 101 sibs with defined phenotypes. 
Penetrance in Sons and Daughters of Obligate Carrier Females 
As there were 80 mentally impaired sons out of a total of 188, a 
penetrance of 85% (95% confidence limits: 72-98%) could be deduced for 
carrier males (Fig. la). 
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Fig. la. Penetrance of the fra(X) gene in males. 
Sons of carrier females. 
Brothers of normal transmitting males. 
Y axis: Ρ value of Chi-square test. The top of the curve corresponds to 
the estimated penetrance, whereas a horizontal line can be drawn to 
indicate the 95% confidence limits for the penetrance. 
For carrier females, fifty-one mentally impaired daughters out of a total of 
159 resulted in a penetrance of 64% (95% confidence limits: 52-79%) 
(Fig. lb). 
In Table I, the penetrance in sons and daughters of mentally normal and 
borderline carrier mothers in relation to the grandparental origin of the fra(X) 
gene is presented. 
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Fig. lb. Penetrance of the fra(X) gene in females. 
daughters of carrier females. 
sisters of normal transmitting males. 
For further details see legend to Fig. la. 
The penetrance in sons appears to be influenced by the grandparental origin 
of the fra(X) gene. We observed full penetrance (95% confidence limits: 78-
100%) in sons who carry the grandpaternal fra(X) gene, whereas 76% 
(confidence limits: 49-100%) of the sons who carry the grandmaternal fra(X) 
gene were affected. The highest penetrance in this latter group was seen in 
sons of mentally borderline mothers, namely 86% (95% confidence limits: 
44-100%) versus 69% (95% confidence limits: 36-100%) in sons of mentally 
normal mothers. The penetrance in daughters of carrier females is not related 
to the grandparental origin of the fra(X) gene, as daughters of mentally 
normal mothers carrying the grandpaternal or grandmaternal fra(X) gene 
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TABLE I: Penetrance in Children of Mentally Normal and Borderline 
Female Carriers Related to the Origin of the Fra(X) Gene. 
Origin fra(X) Mother N Sons N Daughters N 
mental status penetrance % penetrance % 
Normal 41 100 70 56 57 
Grandpaternal Borderline 1 0 1 100 2 
Unknown 0 
Normal 18 69 29 57 28 
Grandmaternal Borderline 13 86 21 100 19 
Unknown 4 91 11 50 4 
Unknown 23 71 56 61 49 
Overall 100 85 188 64 159 
showed penetrances in the same range, 56% and 57%, respectively. Full 
penetrance (95% confidence limits: 58-100%) was found in daughters of 
borderline intelligent mothers. These borderline intelligent mothers received 
in all but one the maternal fra(X) mutation. 
Penetrance in Brothers of Normal Transmitting Males 
For several years, identification of NTM's could be accomplished only 
by pedigree analysis and DNA-linkage studies. Recently, NTM's and non-
expressing carrier males of the fra(X) mutation can easily be recognized at 
the molecular level by an increased CGG fragment length. Figure 2 shows 
some examples of the length variation of the PstI restriction fragment 
encompassing the CGG repeat. A fra(X) family over 3 generations is shown, 
including a NTM and his mentally normal brother. The grandfather of the 
affected children had already been proven to be a NTM by DNA-linkage 
analysis with the tightly linked flanking markers VK23B (DXS297) and 
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Fig. 2. Southern blot analysis of the CGG repeat length in a three generation 
fra(X) family (268/FX). DNA's were cleaved with PstI and blots were 
hybridized with the 600 bp XhoI-PstI fragment just 3' of the CGG-repeat 
sequence. In the mentally normal brother of a normal transmitting male 
(lane 1) the normal 1.0 kb fragment length is replaced by a fragment of 
1.3 kb. The same increased fragment length is seen in lane 2, which 
contains DNA from the normal transmitting male. Lane 4 (an obligatory 
carrier female with the paternally inherited fra(X) gene) shows a fragment 
of normal length, a fragment of increased length at 1.3 kb and a dispersed 
segment > 1.7 kb. Lane 6 displays a normal fragment of 1.0 kb as well as 
a dispersed segment of >3.0 kb of the affected daughter. Lane 7 contains 
DNA from the affected son who shows a dispersed segment of >3.5 kb. 
Lane 3 and 5 show the normal fragments of the two spouses. 
pU6.2 (DXS304). A fragment of increased length which replaces the normal 
one can be observed in the NTM (lane 2) as well as in his mentally normal 
brother (lane 1). 
Twenty-one males were identified as NTM's on the basis of extensive 
pedigree analyses. In 12 cases this could be confirmed by DNA-linkage 
studies using flanking markers (accuracy >99%). Eleven of the 12 
molecularly studied NTM's were also tested by direct analysis of the CGG 
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repeat, which showed an increase in length ranging from 0.2-0.5 kb (Smits et 
al., 1992b), so that the diagnoses were confirmed. 
The penetrance of the fra(X) gene in brothers of NTM's was analysed in 44 
individuals with defined phenotype. In 3 cases, anamnestic information 
demonstrated mental impairment, which resulted in a penetrance of 14% 
(95% confidence limits: 4-37%) (Fig.la). In 2 of the 3 mentally impaired 
brothers it was impossible to confirm the presence of the fra(X) syndrome 
because they were already deceased. The third male was indeed mentally 
impaired and found to be fra(X) positive upon cytogenetic investigation. 
Nine phenotypically normal brothers of NTM's also turned out to be NTM's. 
This result was obtained by pedigree analysis, while in 2 families the 
diagnosis was confirmed by DNA-linkage analysis using marker RS46 
(DXS548), as well as by direct evaluation of the CGG repeat length (Fig.2). 
In another family 3 NTM's, including the index NTM, were identified. One 
of them was deceased but could be identified via the use of flanking markers, 
proximal pVK23 (DXS297) and distal pStl4 (DXS52), in his offspring. The 
other 2 NTM's were recognized by flanking markers as well as direct 
detection of an 0.4 kbp increase of the CGG repeat. 
Penetrance in Sisters of Normal Transmitting Males 
Penetrance of the fra(X) gene in sisters of NTM's was analyzed in 57 
cases. Six females showed mental impairment which results in a penetrance of 
21% (95% confidence limits: 10%-43%) (Fig.lb). Two of the 6 affected 
sisters were cytogenetically tested and showed 9% and 2% fra(X) expression, 
respectively. The female with 2% fragile site expression was also tested for 
the CGG repeat length and showed an increased fragment which presented as 
multiple recognizable bands (defined smear). The fragment size from which 
this smear developed upwards was 1.5 kbp. 
Sixteen phenotypically normal sisters appeared to be carrier because the 
fra(X) syndrome was manifest in their offspring. Another 6 mentally normal 
sisters were cytogenetically tested and all were negative. However, flanking 
DNA markers pointed to carrier ship of the fra(X) gene in 3 of them. This 
result was confirmed by direct detection of the CGG repeat length, as judged 
from Southern blots of EcoRI digests. In these 3 carrier sisters of NTM's an 
increase in CGG repeat length of 0.1 kbp was seen. 
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DISCUSSION 
It is well established that apparently unaffected males are able to transmit 
the fra(X) gene to their daughters (Martin and Bell, 1943; Webb et al., 1981; 
Fryns and Van den Berghe, 1982; Gardner et al., 1983; Froster-Iskenius et 
al., 1984; Pembrey et al., 1984; Brown et al., 1985; 1987; Howard-Peebles 
and Friedman, 1985; Loesch et al., 1987; Holmgren et al., 1988). Most of 
these reports do not mention affected brothers and sisters of such NTM's. 
Assuming that there is no segregation distortion (Sherman et al., 1988), we 
observed a strongly reduced penetrance (mental impairment) in brothers as 
well as in sisters of NTM's: 14% and 21%, respectively, against 85% in sons 
and 64% in daughters of carrier females. (Fig. la and lb). Sherman et al. 
(1985) noted an even lower penetrance of 10% in sisters of NTM's. 
However, such an extreme low penetrance might be caused by the POINTER 
program, as used by Sherman et al. (1985]), which leads to an underestimate 
of the penetrance in females (de Haan et al., 1992). 
The penetrance in daughters of carrier females appears to be considerably 
higher than the overall penetrance in females reported earlier, 64% versus 
35% (Sherman et al., 1985). This discrepancy might be explained by the 
absence of daughters of NTM's who are always non penetrant, or by different 
ascertainment corrections (de Haan et al., 1992). Although our estimate of 
64% penetrance in females is somewhat higher than the approximately 50% 
penetrance obtained in a number of other studies (Fishburn et al., 1983; 
Turner and Jacobs, 1983; Sherman et al., 1988; Navajas and Vianna-
Morgante, 1989; Cronister et al., 1991), such a discrepancy might be 
explained to a large extent by the different criteria of mental impairment. In 
our study, all females who were learning-disabled according to school criteria 
were classified as mentally impaired. Loesch and Hay (1988) reported that up 
to 85% of heterozygotes demonstrated cognitive deficits. We detected such a 
high penetrance in daughters who received the grandmaternal fra(X) gene via 
their borderline functioning mother (Table I). An equally high penetrance in 
daughters of mentally impaired mothers was recently reported by Cronister et 
al. (1991). In carrier daughters who received the fra(X) gene from their 
mentally normal mother a much lower penetrance independent of the 
grandparental origin of the gene was seen. 
The penetrance of the fra(X) gene in sons of carrier females is in the same 
range as the overall penetrance in males reported earlier (Sherman et al., 
1985). The mentally borderline mothers as well as the mothers who carry the 
paternal fra(X) gene contributed to the high penetrance in sons of carrier 
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females. It is tempting to speculate that NTM's would have received the 
grandmaternal fra(X) gene via their mentally normal mother. However, we 
were able to detect the grandpaternal fra(X) gene in 3 non-expressing males 
who were identified by DNA-linkage analysis in combination with direct 
detection of the CGG repeat length. Anamnestic information regarding the 
mental status of mothers of NTM's is difficult to obtain, as most of them had 
to be traced back at least 4 generations ago. In the 12 cases in which we 
could obtain reliable anamnestic information, no evidence for the presence of 
mentally borderline mothers of NTM's was found. 
Our results have important implications for genetic counseling as they indicate 
that clustering of non-expressing fra(X) carrier males and females is a 
common phenomenon. We found no evidence that the reduced penetrance in 
mentally normal sibs of NTM's is caused by a segregation distortion of the 
fra(X) gene, as 25 out of the 28 expected carrier females could be positively 
identified by either pedigree and/or DNA analyses. This implies that mentally 
normal sibs of affected males have considerably less risk of carrying the 
mutated gene, compared to sibs of NTM's. Based on this study, the risk for a 
brother of an affected male is 13%, while the risk for a brother of a NTM is 
46%. The same holds true for mentally normal sisters of affected brothers 
who have 26% risk to carry the fra(X) gene, while sisters of NTM's have a 
risk of 44%. Therefore, an early identification of NTM's is of great 
importance for timely carrier detection, particularly in branches of pedigrees 
in which no clinical or cytogenetic expression of the fra(X) syndrome is 
manifest. This can be achieved readily now the fra(X) gene has been 
characterized (Bell et al., 1991; Oberlé et al., 1991; Verkerk et al., 1991; Yu 
et al., 1991) and NTM's can be identified via CGG trinucleotide repeat 
analysis. 
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SUMMARY 
Direct estimate of the penetrance of the fra(X) gene was compared with 
the estimate using the Pointer computer program. Direct estimate gave overall 
penetrances of 85% for male and 64% for female carriers. The estimates 
calculated by the Pointer program were 82% for males and 38% for females. 
It is argued that the use of the Pointer program gives incorrect estimates of 
the penetrance of the fra(X) gene. 
INTRODUCTION 
The fragile X (fra(X)) syndrome is a familial X-linked form of mental 
retardation. The syndrome is known to have incomplete penetrance in males 
as well as in females. Recently, Smits et al. (1992a) reported estimates of the 
overall penetrance, as defmed by mental impairment, for males (85%) and 
females (64%) in the offspring of obligate female carriers. Especially, the 
estimate reported for daughters differed significantly from the 35% 
penetrance in females published by Sherman et al. (1985). This large 
difference in penetrance has considerable implications for genetic counseling. 
The purpose of this study was to investigate this discrepancy. We addressed 
the question whether this discrepancy arose because of different populations 
or because of different analysis of the data. 
MATERIALS AND METHODS 
Direct Estimate of the Penetrance 
The direct method of estimating the penetrance, as defined by mental 
impairment, started with examining 77 pedigrees for obligate fra(X) female 
carriers. To avoid ascertainment bias the proband families (proband, sibs and 
parents) were omitted. The offspring of the obligate female carriers were 
investigated. A total of 100 obligate female carriers with 347 children was 
incorporated in this part of the study. The direct estimate of the penetrance 
for males is twice the relative frequency of affected males in the offspring. 
The same procedure gives direct estimates for females. Persons with 
significant learning disabilities according to school criteria were classified as 
affected. 
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TABLE I: Complex Segregation Analysis with the Pointer Program 
(77 Pedigrees). 
+ 
Model constant 
Estimations of the 
parameters of the model 
m 
Derived 
penetrance values 
males females 
1 740.84 0.50 15.94 0.00054 (0.90) 0.81 0.38 
2. 740.84 (0.50) 15.99 0.00054 (0.90) 0.81 0.38 
3. 742.69 0.51 15.64 0.00054 (0.80) 0.81 0.38 
4. 742.69 (0.50) 16.00 0.00054 (0.80) 0.82 0.38 
Parameters in parenthesis are fixed 
χ
2
 + constant: -2 ln(likelihood) to which the Pointer program 
omits a constant value independent of the model parameters 
Estimate of the Penetrance Using the Pointer Program 
Complex segregation analysis was performed on the above mentioned 77 
pedigrees by the Pointer program developed by Morton et al. (1983). Only 
families which fulfilled the same criteria as used by Sherman et al. (1985) 
were incorporated in our study. This resulted in 244 families with 984 
children that were used in the Pointer analysis. 
In short, the following parameters were used. The selection coefficient, "m", 
against males is the probability of no transmission of the fra(X) gene for 
males. The population gene frequency is denoted by "q" and the dominance 
for females by "d". A higher "d" results in a higher penetrance, d=0 means 
recessive, d = l means dominant. Furthermore, the parameter "t" gives a 
measure for the distance (on a liability scale) between male carriers versus 
normal males, a higher "t" results in a higher penetrance. This distance is 
assumed to be the same as the distance between the two homozygous female 
classes. Other parameters in the model were fixed on the default values. The 
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ascertainment probability was set on 0.05. See Sherman et al. (1985) for the 
full description of the parameters of the model used by the Pointer program. 
The estimates of the population prevalence of males and females were set on 
0.00044 and 0.00041 as used by Sherman et al. (1985). A number of models 
were fitted. Each model gives estimates of the penetrances in male and female 
carriers. 
RESULTS 
Direct Estimate of the Penetrance 
As there were 80 mentally impaired male offspring out of 188, a 
penetrance of 85% could be deduced for male carriers. For females, 51 
mentally impaired offspring out of 159 resulted in a penetrance of 64% for 
female carriers. 
Estimate of the Penetrance Using the Pointer Program 
Four different models were fitted. The models differed on the selection 
coefficient, m=0.80 and m=0.90, respectively, and on the possibility to 
iterate the dominance parameter. The results of the fitted models are 
presented in Table I. Fixing the dominance parameter or free iteration gives 
for both selection coefficients the same estimates. The estimates of the 
penetrance are almost the same for all 4 models and are similar to the 
estimates of Sherman et al. (1985). 
DISCUSSION 
In this study it is demonstrated that estimates of the penetrance by the 
computer program Pointer are different from those directly deduced. In 
particular, the 38% penetrance of the fra(X) gene in female carriers obtained 
by the Pointer program differs dramatically from the 64% penetrance 
estimated by the direct method. It might be argued that the direct estimate is 
too high because of insufficient ascertainment correction, in particular by not 
talcing into account the patients or obligate carriers which were used to 
establish carrier ship in relatives of the proband families. To test this 
assumption, we also removed from the data set all offspring which was used 
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to establish carriership of the mother. The resulting direct penetrance estimate 
of 61% for daughters of obligate carriers was only fractional lower than 
without this extra ascertainment bias correction. We may conclude that 
insufficient ascertainment correction cannot be held responsible for the 
discrepancy between the results of the Pointer program versus the direct 
estimate. On the other hand, the low estimate calculated by the Pointer 
program might have been caused by the inclusion in the data set of normal 
transmitting male families. Daughters of normal transmitting males do express 
the gene very rarely (Sherman et al., 1985; Smits et al., 1992a) and inclusion 
of these females in the data set might have caused the lower penetrance in 
female offspring as calculated by the Pointer program. However, reanalysing 
the same dataset without the 29 families of normal transmitting males resulted 
in the same estimates of the penetrance. Even using the Pointer program to 
analyse only the families of obligate female carriers did not affect the 
penetrance. Therefore the conclusion that the Pointer program gives 
artificially low penetrance values for female carriers seems inescapable. 
Inspection of the assumptions on which the Pointer program is based suggests 
to us that the direct method results in more reliable data than the computer 
program. In the theory on which the Pointer program is based we found in 
the derivation of the transition matrices in the case of a sex-linked disease the 
following assumption (Morton and Yashuda, 1979): "The selection coefficient 
is taken to be m against the A' gene in males, but is negligible in females." 
For most sex-linked diseases this is a correct assumption, but in the fra(X) 
syndrome affected females do not have a negligible selection coefficient. Of 
the 51 mentally impaired females in our study 32 were adults. Of those 32 
adults 13 were not self-supporting (institutionalized). The reduced 
reproductive fittness of the retarded females is not compensated by a larger 
number of offspring of the mildly retarded carrier females. In our material, 
mildly impaired mothers do not have more children on the avarage than 
normal mothers (Smits et al., 1992b). This gives an estimate of the selection 
coefficient for females of (13/32) times 64% = 26%. If, as in the fra(X) 
case, the selection coefficient against females is wrongly chosen to be zero, it 
follows implicitly that the gene frequency in females (and to a lesser degree 
also in males) will be overestimated. With the same prevalence (that is the 
number of affected individuals in the population) this results in an 
underestimate of the penetrance (number of affected divided by number of 
carriers). Furthermore, the estimation of the penetrance by the Pointer 
program strongly depends on the prevalence, for which precise data are 
lacking. 
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We conclude that it is incorrect to use the Pointer program for estimating 
penetrance and gene frequency in the fra(X) syndrome. The same will hold 
for other sex-linked diseases with positive selection against females. 
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SUMMARY 
The fragile X (fta(X)) syndrome is the most frequent form of inherited 
mental retardation, and co-segregates with a fragile site at Xq27.3 as well as 
with insertion of a variable number of trinucleotide repeats in the 5'-end of 
the FMR-1 gene. As the fra(X) gene is transmitted by females as well as 
males, we have investigated whether the parental origin of the fra(X) gene has 
an effect upon the cytogenetic expression and CGG repeat length. An 
increased fragment length of 0.2 - 0.6 kb appeared to be associated with a 
very low expression or even complete absence of the fragile site as well as 
with a normal phenotype, and was seen mostly in cases of paternal 
inheritance. However, in most female carriers with the maternally inherited 
fra(X) gene we found dispersed fragments ranging from 1.4 - 6.5 kb or even 
complete absence of a hybridization signal. Within the group of female 
carriers with the maternally inherited fra(X) gene we found a statistically 
significant correlation between the level of the cytogenetic expression and the 
PstI restriction fragment length encompassing the CGG repeat. These data can 
be taken as indirect evidence that CGG repeat length and cytogenetic 
expression are causally related. 
INTRODUCTION 
In the fragile X (fra(X)) syndrome, which is considered to be the most 
common familial form of X-linked mental retardation, an unusual mode of 
inheritance is seen. In contrast to many other severe X-linked diseases, the 
fra(X) gene can be transmitted by phenotypically normal males and 
penetrance is appreciable in females (Sherman et al., 1984; 1985; Tommerup, 
1989; Smits et al., 1992). 
Recently, the fra(X) gene has been molecularly cloned and sequenced in part 
(Oberlé et al., 1991; Yu et al., 1991; Verkerk et al., 1991). Carriers can be 
discriminated on the basis of an increase in length and dispersion of a 
restriction fragment in the 5'-end of the FMR-1 gene (Oberlé et al., 1991; Yu 
et al., 1991). It is thought that the length variation of this restriction fragment 
is due to the expansion of a CGG trinucleotide repeat (Kremer et al., 1991). 
It has been suggested that the extent of the length increase of this segment 
may be associated with the clinical and cytogenetic expression as well as by 
the parental origin of the gene (Oberlé et al., 1991). We have reevaluated our 
extensive fra(X) family material for the CGG repeat length variation. This 
enabled us to compare female carriers with the paternal fra(X) chromosome 
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with the group of female carriers with the maternal fra(X) chromosome. Here 
we confirm that the parental origin of the fra(X) chromosome is a major 
determinant for the length variation of the CGG repeat in female carriers. We 
also demonstrate a significant correlation between the CGG repeat length and 
the cytogenetic expression of the fragile-X site. 
MATERIALS AND METHODS 
Subjects 
From a total of 200 families, we selected 110 obligate female carriers in 
whom mental status assessment, cytogenetic typing and/or Southern blot 
analysis was done. It was established by pedigree analyses that 41 females 
carried the paternal fra(X) gene and 69 females the maternal fra(X) gene. The 
mental status in the female carriers was classified as normal, borderline or 
retarded. Borderline was defined as mildly affected (learning disabilities) but 
self-supporting in society. Retarded females were moderately affected and not 
self-supporting in society. 
Cytogenetic Analysis 
Peripheral lymphocytes of all carriers were cultured for 92 hours in 
medium TC 199, supplemented with 5% fetal calf serum. Chromosome slides 
were made according to routine procedures. One hundred metaphases of each 
individual were examined for the presence of a fra(X) chromosome after solid 
Giemsa staining. Potential fra(X) chromosomes were photographed, 
destained, and subsequently GTG-banded for evaluation. 
DNA Analysis 
CGG repeat length was assessed via Southern blot analysis of PstI and 
EcoRI digested total genomic DNA. The blots were hybridized with a 600 bp 
XhoI-PstI fragment just 3' from the CGG repeat (Verkerk et al., 1991) as 
described in detail in the accompanying paper (van Oost et al., 1992). Only 
those carriers were included in this study in whom a normal size EcoRI 
and/or PstI fragment with a single dose intensity, representing the normal X-
chromosome, was observed. For the abnormal chromosome the PstI and 
EcoRI fragment sizes were classified as follows: (i) uniform fragment of 
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normal length and normal intensity (either the 1.0 kbp PstI or the 5.1 kbp 
EcoRI fragment), (ii) uniform fragment of increased length and a single-dose 
intensity, (iii) multiple recognizable bands of reduced intensity identified by 
the fragment size from which the smear developed upwards, (iiii) complete 
absence of hybridization signal with an apparently normal amount of DNA 
present in the lanes. As the signals derived from the PstI digests allowed a 
better classification of the hybridization patterns, all within- and inter-group 
comparisons were based primarily on the PstI digests. 
RESULTS 
Paternal Transmission 
Thirty-seven of 41 females, who inherited the paternal fra(X) gene, 
showed no fra(X) expression. The other 4 female carriers showed only 1-2% 
expression of the fragile site. Both cytogenetically negative and 
cytogenetically positive carriers were mentally normal, and the average ages 
in both groups of, respectively, 42 and 41 years did not differ significantly. 
In Figure 1 the length variation in the CGG repeat containing restriction 
fragments is shown in a fra(X) family over 3 generations. The grandfather of 
the affected children was identified as normal transmitting male by pedigree 
analysis (grandchildren of his brother were also affected) and DNA-linkage 
analysis with the linked markers JH89 (DXS539) and F814 (DXS52) flanking 
the fragile site (Dreesen et al., unpublished data). In the cytogenetic positive 
and mentally retarded male patient, a dispersed signal is seen for both the 
EcoRI and PstI digests (Fig. la,b, lane 4). The apparent increase in size, as 
judged from the best discernible signal, was at least 1500 basepairs for the 
EcoRI digest and at least 3000 basepairs for the PstI digest. The apparently 
larger increases in PstI fragment length as compared to EcoRI was a 
consistent finding in all patients studied (unpublished data). In the PstI digest 
of DNA from the grandfather an abnormal fragment replacing the normal one 
is seen (Fig. lb, lane 1). His daughter shows, besides the normal size band 
representing the normal maternal X-chromosome, a fragment of increased 
length slightly smaller in size as the one seen in her father (Fig. lb, lane 2). 
For the EcoRI digests qualitatively similar data were obtained but, due to the 
limited resolution of the agar electrophoresis, the size differences were less 
pronounced (Fig. la, lanes 1 & 2). The Pst I digests of in total 32 female 
carriers with the paternal fra(X) gene were analysed for the CGG repeat 
length and 29 out of this group showed a well defined fragment which was 
increased in length from 0.2 - 0.6 kb (Table I). The average increase in PstI 
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Fig. 1. Southern blot analyses of a three generation fra(X) family (161/FX). 
Blots were hybridized with the XhoI-PstI fragment just 3' of the CGG 
repeat sequence. Lane 5 contains DNA from the unaffected spouse. For 
further details see text. A: EcoRI digest; B: PstI digest. 
fragment length of 410 basepairs in the cytogenetic positive group (n=3) was 
not significantly different from the average increase in PstI fragment length of 
380 basepairs seen in the cytogenetic negative group. Three female carriers, 
of which one had 1% cytogenetic expression, showed a slightly dispersed 
signal in the same size range. 
Maternal Transmission 
Female carriers who inherited the maternal fra(X) gene (n=69) were 
classified according to their mental status and cytogenetic expression (Table 
II). Only 5 out of a group of 15 mentally normal females demonstrated 
cytogenetic expression, with a range from 1% to 14%. All borderline and 
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TABLE I. Distribution of CGG Repeat Length in Cytogenetic Negative 
and Positive Females Carrying the Paternally Inherited Fra(X) 
Gene. 
CGG Repeat Length in Kbp (PstI fragment) 
Normal* Increased Defined0 Absence Total 
fragment fragment smear signal 
Cytogenetic 
Negative 0 26 2 0 28 
Cytogenetic 
Positive 0 3 1 0 4 
Total 0 29 3 0 32 
a: Uniform fragment of normal length and normal intensity (1.0 kbp). 
b: Uniform fragment of increased length and single-dose intensity, ranging in size 
from 1.2-1.6 kbp. 
c: Multiple recognizable bands of reduced intensity identified by the fragment size 
from which the smear developed upwards. In this sample the fragment were 
only slightly dispersed over a range of 1.45-1.50 kbp. 
d: Complete absence of hybridization signal with an apparently normal amount of 
DNA present in the lanes. 
mentally retarded females (n=54) were cytogenetically positive. The mean 
fra(X) expression of these latter 2 groups was 14% (range l%-32%) and 16% 
(range 2%-53%), respectively. DNA isolated from 55 females with the 
maternally inherited fra(X) gene was analysed for the CGG repeat fragment 
length. The hybridization pattern typical for this group of carriers is also 
shown in Figure 1. 
In the EcoRI digest a single dose intensity is seen for the normal sized 
fragment, while the remainder of the signal is apparently dispersed over 
various fragments of 8.0 kbp and higher (Fig. la, lane 3). In the PstI digest a 
clearly dispersed signal is seen as well, but the normal fragment is less well 
defined (Fig. lb, lane 3). In 14 cytogenetic positive female carriers with the 
maternal fra(X) gene, complete absence of the hybridization signal was found, 
indicating a very extensive dispersion of the fragment length. In 41 female 
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TABLE Π: Mental Level in Cytogenetic Negative and Positive Females 
Carrying the Maternally Inherited Fra(X) Gene. 
Mental level 
Normala Borderline15 Retarded0 Total 
Cytogenetic Negative 10 0 0 10 
Cytogenetic Positive 5 30 24 59 
Total 15 30 24 69 
a: No obvious signs of mental disabilities. 
b: Mildly affected females, cognitive ability can occasionally be in the normal 
range, but significant learning disabilities were always present. They are self-
supporting in society. 
c: Moderately affected females, not self-supporting in society and in some cases 
institutionalized. 
carriers a fragment of increased length, ranging in size from 1.2 kb to 6.5 kb, 
was found (Table III). To investigate whether there was a relation between 
the frequency of cytogenetic expression and CGG repeat length, a Pearson 
correlation test was performed for this group. A statistically significant 
positive correlation (r= 0.43, Ρ <0.01) was found between the level of 
fra(X) expression and CGG repeat length (Fig. 2). 
DISCUSSION 
We show here that the increase of the CGG repeat length in female 
carriers with the paternal fra(X) gene varies from 0.2 - 0.6 kb and is mostly 
seen as a homogeneous band on Southern blots. However, in most carrier 
females with the maternal fra(X) gene a dispersed hybridization signal with an 
apparent length increase in the range from 0.2 - 5.5 kb is observed. Our data 
are in general agreement with the classification proposed by Oberlé et al. 
(1991) in that 2 distinct classes of fra(X) mutations can be observed, namely 
the short inserts and the much larger and dispersed inserts. The present study 
confirms that the origin of the fta(X) gene is a major determinant for the 
cytogenetic expression and mental status of the female carriers. In particular, 
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TABLE Ш. Distribution of CGG Repeat Length in Cytogenetic Negative 
and Positive Females Carrying the Maternally Inherited 
Fra(X) Gene 
CGG Repeat Length in Kbp (PstI fragment) 
NormaIa Increased Defined0 Absenced Total 
fragment fragment smear signal 
Cytogenetic 
Negative 0 4 2 0 6 
Cytogenetic 
Positive 0 0 35 14 49 
Total 0 4 37 14 55 
a: Uniform fragment of normal length and normal intensity (1.0 kbp). 
b: Uniform fragment of increased length and single-dose intensity, ranging in size 
from 0.2-0.4 kbp. 
c: Multiple recognizable bands of reduced intensity identified by the fragment size 
from which the smear developed upwards. In this sample the fragment were 
only slightly dispersed over a range of 1.4-6.5 kbp. 
d: Complete absence of hybridization signal with an apparently normal amount of 
DNA present in the lanes. 
all females who carry the paternal fra(X) gene are mentally normal and 
demonstrate no cytogenetic expression or only at a very low frequency, which 
is in agreement with Sherman et al. (1985). 
In females who inherited the maternal fra(X) gene, cytogenetic expression 
appears to be linked with the mental status. While all mentally borderline and 
retarded women were fra(X) positive, only a third of the mentally normal 
females showed fra(X) expression. The level of fra(X) expression between 
mentally retarded and borderline female carriers is not significantly different 
(Wilcoxon, Ρ >0.68), which is in agreement with other reports (Sherman et 
al., 1985; Borghgraef et al., 1990; Grigsby et al., 1990; Bell et al., 1991). 
Yu et al. (1991) have reported that there is no obvious direct relationship 
between the CGG repeat length and mental status. Recently, Rousseau et al. 
(1991) reported that 53% of the female subjects in which the repeat sequence 
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Fig. 2. Linear regression of the relation between increased PstI fragment length 
(uniform fragment of increased length and multiple recognizable bands 
from which the smear developed upwards) and cytogenetic expression in 
females, carrying the maternally derived fra(X) gene (n=41). 
was at least a defined smear (full mutation) were mentally impaired. We have 
found in 14 cytogenetic positive female carriers with the maternal fra(X) gene 
a complete absence of hybridization signal, indicating extensive dispersion of 
the CGG repeat. None of these carriers was mentally normal. The possible 
correlation between mental status and repeat length in all carrier females 
needs to be evaluated in more detail. 
The observed effect of the origin of the fra(X) gene on both the cytogenetic 
expression and the CGG repeat length suggests that both phenomena are 
causally related. Indeed, in the group of female carriers with the maternal 
fra(X) gene, we did find a statistically significant correlation (r=0.43) 
PstI fragment 
length (kbp) 
6 · 
5 • 
4 · 
3 • 
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ι • 
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between the level of cytogenetic expression and the CGG repeat length. Our 
observations confirm the preliminary results of Oberlé et al. (1991) and Yu et 
al. (1991), that the degree of increase of the CGG repeat length is associated 
with the frequency of cytogenetic expression and lends further support to the 
hypothesis put forward by Kremer et al. (1991) that the amplification of the 
CGG repeat causes the cytogenetic instability. 
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SUMMARY 
We have evaluated our carrier testing for the fragile X (fra(X)) syndrome, 
which was based on linked DNA markers, with the direct analysis of the 
CGG repeat sequence in the fra(X) gene. PstI and EcoRI blots were 
hybridized with a probe derived from the region just 3' of the CGG repeat in 
Xq27.3. We found the mutation analysis to be very sensitive as all 71 obligate 
gene carriers as well as 135 fra(X) patients tested showed evidence for an 
increased restriction fragment length encompassing the CGG repeat sequence 
with or without dispersion of the hybridization signal (mosaicism). Based on 
linked DNA markers, 6 out of 50 cytogenetic negative and mentally normal 
males at risk and 15 of 72 females at risk had inherited the allele at risk. All 
of these diagnoses could be confirmed by analysis of the CGG repeat length. 
INTRODUCTION 
Counselling of families in which the fragile X (fra(X)) syndrome 
segregates is problematic as female but also male carriers of the fra(X) gene 
may be without any symptoms. Cytogenetic analysis of the fragile site at 
Xq27.3 has its limitations as it has become clear that the expression of the 
fragile site in mentally normal gene carries is mostly negligible (Smits et al., 
1992). In the past we have employed linked DNA markers for the 
identification of asymptomatic gene carriers and have offered this test as an 
integral part of our genetic service. Now that the fra(X) gene has been cloned 
(Verkerk et al., 1991), and is associated with an expansion of a CGG repeat 
sequence (Oberlé et al., 1991; Yu et al., 1991; Kremer et al., 1991; Fu et 
al., 1991), direct mutation analysis is possible based on the indirect analysis 
of the expansion of the CGG repeat in the 5'region of the FMR-1 gene. We 
have reanalyzed our family material for this CGG repeat sequence and were 
able to classify correctly patients, asymptomatic obligate gene carriers, as 
well as to confirm our carriership predictions based on linked DNA markers. 
MATERIAL AND METHODS 
Linkage Analysis 
Fra(X) families were diagnosed cytogenetically and tested for restriction 
fragment length polymorphisms essentially as described before (van Oost et 
al., 1991). The polymorphic markers used for linkage were pRNl (DXS369) 
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(Oostra et al., 1990), pJH89 (DXS539) (van den Hurk et al., 1991), pVK23B 
(DXS297) (Suthers et al., 1990), RS46 (DXS548) (Riggins et al., 1992), 
VK21A and VK21C (DXS296) (Suthers et al., 1989), 11-10 (DXS466) 
(Hulsebos et al., 1991) and pU6.2 (DXS304) (Dahl et al., 1989). Risks for 
carriership for the consultands were calculated with the MLINK program of 
the LINKAGE package version 5.03 (Lathrop et al., 1984). Penetrance of the 
cytogenetic aberration in males and females were estimated to be 0.9 and 
0.64, respectively and the gene frequency was taken as 0.001. 
Direct Mutation Analysis 
The probe used for the detection of the fra(X) mutation was a 600 bp 
XhoI-PstI subclone derived from the 5.1 kbp EcoRI fragment (pA0365) 
which encompassed the CGG-repeat sequence (Verkerk et al., 1991). Under 
standard hybridization and washing conditions (van Oost et al., 1991) a clear 
single copy signal could be obtained with this probe in control individuals. 
The PstI and EcoRI fragment sizes were classified as follows: (i) uniform 
fragment of normal length and normal intensity (either the 1.0 kbp PstI or the 
5.1 kbp EcoRI fragment), (ii) uniform fragment of increased length and a 
single-dose intensity, (iii) multiple recognizable bands of reduced intensity 
identified by the fragment size from which the smear developed upwards, (iii) 
complete absence of hybridization signal with apparently normal amount of 
DNA present in the lanes. The amount of DNA on the blots was estimated 
from the ethidium bromide stain and was of particular importance in the 
estimation of a double- or single dose intensity of the normal PstI or EcoRI 
fragment in women. 
RESULTS 
Six hundred individuals from 38 families in which the fra(X) gene was 
segregating were tested with the CGG repeat probe. These families were 
tested before with a number of markers on both sides of the fra(X) gene, in 
order to assess the carrier status of relatives at risk. In Fig. 1 a fra(X) family 
(285/FX) is shown which was analyzed for the length of the CGG-repeat 
encompassing PstI and EcoRI fragments. In the grandmother, who was an 
obligate carrier based on genealogie data, a normal sized band and a band of 
increased size was seen. In the PstI digest the increased fragment was 
predominant, while for the EcoRI digest both bands seemed to be of equal 
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Fig. 1. CGG-repeat analysis in a fra(X) family. PstI (a) and EcoRI (b) blots were 
incubated with the pA0365 probe, which hybridizes with the PstI and 
EcoRI fragments which encompasses the CGG repeat sequence in the 
FMR-1 gene. In the margins the approximate lengths of the restriction 
fragments are given. C: constant fragment; solid symbols: mental 
retardation and cytogenetic expression; obligate carriers have center 
circles. 
intensity. In her affected son most of the hybridization signal is dispersed 
over fragments at least 1500 bp increased in size. However, it is clear that 
part of the hybridizing fragments for this patient is only moderately increased 
in size and, in effect, is smaller than the length of the increased fragment 
seen in the mother. Both her daughter and her grand-daughter showed 
perfectly normal hybridization signals for EcoRI as well as PstI. As the 
grandfather was deceased, DNA-linkage analysis based on the flanking 
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markers DXS369 and DXS296 was only informative for the granddaughter. 
The haplotype of the X-chromosome which she inherited from her mother 
was, for these markers, completely different from that of her affected uncle. 
In Fig. 2 a typical fra(X) family is shown with the sibships of 3 daughters of 
a normal transmitting male (identified by extendend pedigree analysis). Both 
patients displayed a dispersed PstI and EcoRI fragment, while in their 
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Fig. 2. CGG-repeat analysis in a fra(X) family with a normal transmitting male. 
For legend see Fig. 1. 
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mothers the size of the PstI and/or EcoRI band was increased 100-400 bp. 
However, also in 2 phenotypically normal granddaughters and one normal 
grandson the PstI and/or EcoRI fragments were 100-400 bp increased, or 
even dispersed as is seen for the daughter of the youngest carrier mother. 
This family was previously typed for the CA repeat RS46 (DXS548). For all 
grandchildren the predicted carrier status was in agreement with the direct 
analysis of the CGG repeat length. In the following the analysis of all family 
data are summarized (Table I). 
TABLE I. Distribution of CGG Repeat Length for Fra(X) Patients, 
Carriers and Control Males and Females. 
CGG Repeat Length in Kb (PstI fragment) 
Normal3 Increased" Defined0 Absenced Total 
fragment fragment smear signal 
Male patients 0 
Female patients 0 
Male carriers 0 
Female carriers 0 
Control males 53 
Control females 22 
Total 75 
0 
0 
11 
52 
0 
0 
63 
57 
34 
0 
5 
0 
0 
29 
15 
0 
1 
0 
0 
86 
49 
11 
58 
53 
22 
96 45 279 
a: Uniform fragment of normal length and normal intensity (1.0 kbp). 
b: Uniform fragment of increased length and single-dose intensity, ranging in size 
from 1.2-1.6 kbp. 
c: Multiple recognizable bands of reduced intensity identified by the fragment size 
from which the 
smear developed upwards. The fragment size from which the smear developed 
was 1.4-9.0 kbp. 
d: Complete absence of hybridization signal with an apparently normal amount of 
DNA present in 
the lane in males. In females a normal sized band of single dose intensity was 
seen only. 
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Repeat Length in Control Persons 
Repeat length in normal individuals was assessed in the family members 
related by marriage. For all 53 males and 22 females studied no increased 
PstI and/or EcoRI fragments were seen. In the PstI digests slight variations in 
fragment sizes were noted in the order of 50 basepairs or less. In females the 
PstI signal was often not discrete but presented itself with a band width of 
about 50 bp with a apparently monotonous decrease in intensity. In no 
instance aberrant fragment sizes were noted in the family members not at 
risk. 
Repeat Length in Mentally Retarded Patients 
In all 135 mentally retarded, cytogenetically positive, fra(X) patients 
studied no normal sized PstI and/or EcoRI fragments were seen. All patients 
showed in PstI digests evidence for a very dispersed signal and in 33% no 
hybridization signal at all was seen. This was taken as evidence that the 
repeat was dispersed beyond the detection limit and was confirmed on the 
basis of the fact that a normal amount of DNA was present on the blot while 
other lanes on the same blot gave clear positive hybridization with the repeat 
probe. In all but 2 male patients an EcoRI fragment of defined increased size 
was seen, probably a reflection that the dispersed fragments were more 
compressed after electrophoresis of EcoRI digests compared to PstI digests. 
Likewise, in 4 female patients, who had received the grandpaternal allele, an 
EcoRI fragment of defined increased size was seen. 
Repeat Length in Mentally Normal Obligate gene Carriers 
Eleven male carriers were identified through extended family studies. In 
all a fragment of defined increased size was observed for PstI and/or EcoRI. 
For the 58 identified female carriers the repeat length depended clearly on the 
origin of the fra(X) chromosome. Most female carriers showed a PstI 
fragment of defined increased size, while in some a dispersed signal was seen 
(Smits et al., 1992). 
Repeat Length in Relatives With a Low Risk Based on Linkage Analysis 
Forty-four males and 57 females at 25 or 50% a-priori risk were found to 
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have a residual chance of being a carrier of less than 10% based on the 
analysis of linked DNA-markers (Table II). In all of these consultants this 
negative result was confirmed by the absence of any aberration in either the 
PstI and/or EcoRI digest. 
TABLE Π. Validation of Linkage-Based DNA-Diagnosis of Fra(X) Gene 
Carriership. 
Risk based on linkage EcoRI and/or PstI fragment2 
analysis1 Normal Increased 
Males 1 % 
4% 
99% 
Females 1 % 
3% 
4% 
5% 
90% 
99% 
Risks were based on phase-known méioses informative for linked DNA-markers 
and calculated with the MLINK program of the LINKAGE package. 
EcoRI and PstI blots were hybridized with the probe just 3' of the CGG repeat 
and the autoradiograms were scored as described in the Material and Methods 
section 
Repeat Length in Relatives With a High Risk Based on Linkage Analysis 
Six males and 15 females at 25-50% risk were found to have inherited the 
allele at risk based on linkage analysis. In all of these cases this positive 
result was confirmed by the presence of either an increased PstI and/or EcoRI 
fragment of defined size. In none of these non-manifesting carriers evidence 
for dispersed fragments was obtained. 
40 
4 
0 
46 
1 
5 
5 
0 
0 
0 
0 
6 
0 
0 
0 
0 
1 
14 
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DISCUSSION 
Counselling of fra(X) families has posed a vexing problem, as many of 
the female as well as the male fra(X) gene carriers are phenotypically normal. 
Linkage-based DNA-diagnosis has been applied initially with markers 
localized relatively far from the disease gene locus (Brown et al., 1988). In 
particular, the limited informativity of these restriction fragment length 
polymorphisms has made the necessary application of flanking markers 
cumbersome (Mulley et al., 1987). The recent development of tightly linked 
CA-repeat polymorphisms have ameliorated these diagnostic problems 
significantly (Riggins et al., 1992; Richards et al., 1992). 
However, direct analysis of the gene defect is always preferable in particular 
in families in which the diagnosis is uncertain and/or in which no patients are 
available for study. This has been demonstrated recently by mutation analysis 
in the fra(X) syndrome (Rousseau et al., 1991; Sutherland et al., 1991; 
Nakahori et al., 1991). In this paper we were able to confirm that the 
expansion of the CGG repeat, as measured by the length of the PstI and/or 
EcoRI fragment, is sensitive and specific. By using the 2 enzymes EcoRI and 
PstI, we were able to score aberrations in all patients, in contrast to all of the 
control individuals. PstI is particular by well suited for the identification of 
normal transmitting males and their carrier daughters. EcoRI, in turn, is more 
suited for analysis of the dispersion of the repeat as is seen in male and in 
female patients. Also, analysis with both restriction enzymes will be of help 
in the evaluation of possible artifacts as is exemplified by the pedigree in Fig. 
1. However, our classification of the variation in the CGG repeat length 
remains tentative. Transitions between the different forms might be present as 
is seen in the patient in Fig. 1. Detailed and more sensitive analysis is needed 
to evaluate all the different size distributions for their diagnostic impact, as 
was also pointed out by Rousseau et al. (1991). 
As positive identification of patients seems straightforward, exclusion of the 
syndrome is less so. In normal individuals slight variations of the PstI 
fragment length were noted frequently. Together with the often observed 
slight smearing of the PstI fragment in normal individuals made this the 
definite exclusion of carrier status problematic. Direct measurement of the 
CGG repeat on both X-chromosomes and identification of heterozygosity 
might be of help in the exclusion diagnosis. Linkage analysis, in particular 
with the highly informative CA-repeats, is likely to keep its own merit in 
exclusion-diagnosis. We also want to point out here that we find the 
aberrations in the repeat length in patients with the full Martin-Bell 
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phenotype. In a fra(X) positive family in which the mental retardation and 
facial characteristics were less pronounced, we did not find any evidence for 
expansion of the CGG repeat (unpublished data). Thus, caution should be 
exercised in direct analysis of the CGG repeat in families in which not all the 
typical facial, mental, and cytogenetic abnormalities occur together. 
By the retrospective analysis presented in this paper we were able to show 
that our initial linkage-based DNA diagnoses were correct for all consultands. 
The risk figures could all be updated to almost certainty. As the CGG-repeat 
expansion could also be found in fetal material, the CGG repeat analysis will 
be the method of choice for postnatal as well as prenatal diagnosis of the 
fra(X) syndrome. 
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SUMMARY 
For genetic counseling in fragile X (fra(X)) families it is important to know 
the diagnostic impact of the CGG repeat length in carriers of the fragile X 
mutation. We have analyzed the CGG repeat length in 106 males and 73 females 
who had inherited the maternal fra(X) mutation. The sensitivity, specificity, and 
the presence of the pre/full mutation for predicting mental retardation as 
measured on Southern blots of Pstl/EcoRI digests, were calculated. In males the 
sensitivity, specificity and negative predictive value were 99%, 100% and 94%; 
respectively. In females the specificity (60%) and, consequently, the positive 
predictive value (82%) was reduced. Therefore, it remains impossible to predict 
accurately whether a female fetus demonstrating a full mutation will be affected. 
On the other hand, the negative predictive value of the CGG test in females was 
100%. We have no evidence, as yet, that for female carriers with the full 
mutation cytogenetic analysis is of additional value to predict the mental status. 
However, we have observed one mentally retarded fra(X) case with extreme 
mosaicism in which a typical premutation fragment was the predominant DNA 
species. Therefore, until more data and better DNA tests are available, we would 
like to advocate additional cytogenetic investigation if in a fetus a CGG repeat 
length in the premutation range is found. 
INTRODUCTION 
Fragile X (fra(X) syndrome, a relatively common type of X-Iinked mental 
deficiency, is caused by an expansion of a trinucleotide repeat p(CGG)n at the 
FMR1 locus in the 5' region of the gene (Kremer et al., 1991; Ober lé et al., 
1991; Verkerk et al., 1991; Yu et al., 1991). This expansion may be expressed 
cytogenetically as a fragile site at the distal long arm of the mutated X-
chromosome. It has been proposed that the length of the CGG repeat correlates 
with cytogenetic expression of this fragile site as well as with phenotype (Oberlé 
et al., 1991; Sutherland et al., 1991; Yuetal., 1991, 1992; Smits et al., 1992a). 
This implies that the variation in CGG repeat length has immediate diagnostic 
applications. In order to examine its diagnostic value, we have analyzed the 
CGG repeat length by Southern blot analysis of digested genomic DNA in a 
large cohort of carriers of maternally inherited fragile X mutation. The 
specificity, sensitivity, and predictive values of the DNA analysis were 
determined. 
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MATERIALS AND METHODS 
Subjects 
From the total offspring (n=347) of obligate fra(X) female carriers, we 
selected 73 females and 106 males who had inherited the FRAXA mutation. 
Inheritance was established through cytogenetic analysis, DNA linkage analysis 
or direct detection of the CGG repeat length and/or by pedigree analysis. 
Maternal transmission of the fra(X) mutation was initially traced by pedigree 
analysis and subsequently confirmed by DNA linkage analysis. Mental status of 
the selected individuals was obtained anamnestically and differentiated as 
normal, borderline, or retarded. Normal mental status implied that no obvious 
signs of mental disability were present. Mentally borderline individuals were 
mildly impaired as they had significant learning disabilities, but were self-
supporting in society. Mentally retarded individuals were moderately affected 
and not self-supporting in society. 
Estimation of the CGG Repeat Length by Southern Blot Analysis 
For routine DNA-diagnosis of the FRAXA mutation we assessed the length 
variation of the CGG repeat by Southern blot analyses of Pstl/EcoRI restricted 
total genomic DNA. In atypical cases in which the genotype to phenotype 
correlation was not consistent, we employed a Bglll digest too, to determine the 
extremely dispersed CGG repeats. The probe used for the detection of the fra(X) 
mutation was a 600 bp XhoI-PstI subclone derived from the 5.1 kbp EcoRI 
fragment (pA0365) which encompasses the CGG repeat sequence (Verkerk et 
al., 1991). 
The PstI and EcoRI fragment sizes were recorded and classified as follows: (i) 
uniform fragment of normal length and normal intensity, (ii) uniform fragment 
of increased length in the premutation range, (iii) heterogeneous fragments above 
the premutation range or complete absence of hybridization signal with a normal 
amount of DNA present in the lane, indicating the presence of a full mutation. 
Only Southern blots with at least 15 different individuals were tested. This 
allowed us a reliable estimate of the dosis on the autoradiogram. The amount of 
DNA actually present on the blot was estimated on a comparative basis from the 
Ethidium Bromide staining in the gel as well as from the back-ground 
hybridization throughout the lanes on the autoradiogram. In our hands this 
method was equal or superior to comparison with a so-called "control probe". 
This conclusion was reached after numerous multiple dosis determinations (data 
96 
not shown). 
RESULTS AND DISCUSSION 
Relation Between CGG Repeat Length and Phenotype 
The results of the length increase of the Pstl/EcoRI fragments in fra(X) 
mutation carriers relative to sex and mental status are summarized in Table 1. 
In case the hybridization signal for PstI was absent (22 males and 15 females), 
EcoRI digests showed in all but one (see below) a heterogeneous smear in the 
full mutation range. 
TABLE I. Length Increase of the Restriction Fragments Encompassing the 
CGG Trinucleotide Repeat in Fra(X) Gene Carriers Relative to 
Sex and Mental Status 
Length increase (kbp) of Pstl/EcoRI 
restriction fragment encompassing the 
CGG trinucleotide repeat 
Group 
Males 
Females 
Mental status 
Retarded 
Normal 
Retarded 
Borderline 
Normal 
Premutation 
1 
15 
0 
0 
15 
Full mutation 
90 
0 
21 
27 
10 
Normal fragment length. No normal sized fragment was observed in any of the 
tested male carriers. Similarly, all tested female carriers demonstrated an 
increased fragment size, representing the abnormal X-chromosome, besides a 
size of normal fragment. 
Premutation. All but one individual with a fragment length in the premutation 
range were mentally normal (n=31). The 26 cytogenetically tested individuals 
from this group (13 males and 13 females) did not express the fragile site. In the 
single mentally retarded male who showed only Pstl/EcoRI fragment sizes in the 
premutation range, 1% of his cultured lymphocytes were positive for the fragile 
X chromosome. In an effort to solve this discrepancy we analyzed also a BG1II 
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digest of this patient. In typical fra(X) patients a distinct restriction fragment of 
increased sizes is seen (fig. 1, lane 5). In this patient a smear was seen for the 
Bglll digest (fig. 1, lane 2,3,4) which indicated an extremely dispersed 
expansion in about 20% of his X-chromosomes. 
Figure 1. 169/FX Bglll 
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Fig. 1. Bglll-Southern blot analysis in a male FRAXA patient with extreme 
mosaicism. The autoradiagram of the Bglll-Southern blot shows in lane 1 the 
DNA fragment length of a normal male and in lane 5 of a mentally impaired 
female carrier with 3% cytogenetic expression of the fragile site. Both 
controls are compared to the patient DNA with 3 different DNA 
concentrations (lane 2 7.5 μ%, lane 3 11.25 /ig, lane 4 15 μg). The patient 
DNA shows a faint heterogeneous smear in contrast to the carrier female 
(lane 5), who shows a discrete band. C= bands are due to back-ground 
hybridization and are seen in all controls and patients. S= smear of 
fragments. 
Full mutation. Heterogeneous fragments in the full mutation range were present 
in all but one (see previous paragraph) mentally retarded male (n=91). Although 
this was an exceptional case, as mentioned before, prudence is called for when 
determining the repeat length based only on Pstl/EcoRI digest. All mentally 
98 
impaired females (η=48) showed the full mutation. Of the 46 mentally retarded 
women who were tested cytogenetically, all but one showed fragile X 
expression. In contrast with males, 10 of the 58 females who carried a full 
mutation were mentally normal. Seven of them were cytogenetically tested and 
5 showed fragile X expression. 
Predictive Value of the CGG Repeat Length Determination 
We have calculated the sensitivity, specificity, as well as the positive and 
negative predictive value encompassing the CGG trinucleotide repeat length, 
using the collected DNA data of Pstl/EcoRI digests (table 2). Sensitivity was 
calculated from the proportion of mentally impaired carriers who were classified 
correctly by the presence of a full mutation. In males as well as in females, this 
sensitivity of the CGG trinucleotide repeat length determination was very high 
(Table 2). 
TABLE Π. Sensitivity, Specificiy, Positive Predictive Values (pVpos), and 
Negative Predictive Values (pNeg) of CGG Repeat Length 
Determination for Fra(X) Syndrome, Using Pstl/EcoRI 
Restriction Enzymes 
Sex 
Male 
Female 
Sensitivity 
99 
100 
Percent 
Specificity 
100 
60 
pVpos 
100 
82 
pVneg 
94 
100 
The specificity of the CGG-repeat test for mental status is determined by the 
proportion of mentally normal carriers who are correctly classified by the 
presence of a premutation. Our calculations show that the specificity of the CGG 
repeat test for male carriers is maximal (100 percent) in contrast with female 
carriers (60 percent). Our data are in agreement with the results published by 
Rousseau et al. (1991) that 100 percent of males who carry the full mutation will 
be mentally impaired. In accordance with Rousseau et al. (1991), Mulley et al. 
(1992) and Yu et al. (1992), we established that females with a full mutation can 
be either normal carriers or mentally affected. 
99 
If these figures for specificity and sensitivity are to be presented as positive and 
negative predictive values the frequency of mental retardation in the target 
population (fra(X) carriers) must be specified. We used the previously derived 
penetrance value of 85% and 64% for males and females, respectively (Smits et 
al., 1992b) and applied the rule of Bayes. The positive predictive value in males 
was 100% and in females only 82%. As 2 categories of mentally impaired 
females were assessed, borderline and retarded, we calculated the positive 
predictive values for both categories. Given the 26% penetrance of mentally 
borderline and 38% penetrance in retarded females (unpublished data), positive 
predictive values of 33% (26/64 χ 0.82) and 49% (38/64 χ 0.82) were obtained, 
respectively. Therefore, it remains impossible to predict accurately whether and 
to which degree a female fetus with a full mutation will be affected. In contrast, 
the negative predictive value of the CGG repeat determination in females is 
100%. This implies that a prenatally diagnosed fetus of the female sex, with a 
small increase in fragment size (premutation), will have less than 1 % percent 
chance to be mentally affected. The presence of one mentally retarded male out 
of a group of 91, who initially showed a premutation using a Pstl/EcoRI digest, 
illustrated that in a case of extreme mosaicism it is difficult to visualize a smear 
typically for an affected individual. Since this retarded male showed fragile X 
expression, it makes the point that cytogenetic testing in cases of a CGG repeat 
length in the premutation range may give additional information about the mental 
status of the carrier. Our data confirm the results of others that, for optimal 
detection of a possible full mutation, the use of Bglll digest is useful (Rousseau 
et al., 1992; Knight et al., 1992; Oostra et al., 1993). However, to date the 
number of directly diagnosed patients showing an extreme mosaicism on Bglll 
digest is not known. Therefore, until more data are available, we would like to 
advocate additional cytogenetic investigation if a fetus carries a premutation. We 
have no evidence as yet, that in fetuses with a CGG repeat length in the full 
mutation range, cytogenetic analysis is of additional value to predict the mental 
status. 
Thus, direct molecular analysis of the CGG repeat length together with PCR-
based genotyping of flanking CA repeats is now the strategy of choice for 
prenatal fra(X) diagnosis. Special care has to be given if a premutation is 
detected. In those cases DNA analysis should be supplemented with cytogenetic 
analysis to exclude extreme mosaicism of the fta(X) mutation, which could lead 
to a false negative prediction of the phenotype. 
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SUMMARY 
The fragile X (fta(X)) syndrome is associated with an expanding CGG 
repeat in the 5' untranslated region of the first exon of the FMR1 gene. 
Subsequent methylation of the promoter region inhibits expression of the 
FMR1 gene. In two clinically normal brothers large, expanded CGG repeats 
and cytogenetically visible fragile sites were found. The FMR1 promoter was 
unmethylated and both RNA and protein could be detected. This indicates that 
inactivation of the FMR1 gene and not repeat expansion itself results in the 
fra(X) phenotype. We conclude that repeat expansion does not necessarily 
induce methylation and that methylation is no absolute requirement for the 
induction of fragile sites. 
INTRODUCTION 
Triplet repeat expansions have been associated with a variety of genetic 
disorders (1-7) and fragile sites (8-11) or both (8, 9). Limited expansion of 
CAG repeats within the coding region of genes cause a number of 
neurodegenerative disorders, probably due to a gain-of-function of the 
protein. Very large, expanding repeats are found in myotonic dystrophy (2) 
and in a number of fragile sites (8-11). As yet, the destructive mechanism of 
the expanded CTG repeat in the 3' untranslated region (UTR) of the DM-
kinase gene is unknown and conflicting reports on over- or underexpression 
of the gene product in patients exist (12, 13). The triplets involved in fragile 
sites are CGG or CCG and clinical features can be present (FRAXA, 
FRAXE) or absent (FRA16A, FRAXF). The best characterized example is 
the FRAXA-site at Xq27.3 (14, 15), indicative of the fra(X) syndrome, which 
is the most common form of hereditary mental retardation in males (16-18). 
The disease is associated with expansion of a CGG repeat, located in the 
5'UTR of the FMR1 gene. Methylation of the FMR1 promoter region silences 
the gene (19-23) and absence of the FMR1 protein results in the clinical 
phenotype. This is supported by a rare group of patients showing the clinical 
features of the fra(X) syndrome, but who were cytogenetically negative. In 
these patients deletions (24-26) or a point mutation (27) in the FMR1 gene 
were demonstrated, which resulted in the absence of or a defective FMR1 
protein. 
So far, several groups have tried without success to find a correlation between 
the number of CGG triplets and the severity of mental retardation (28, 29). It 
turned out that the methylation status of the FMR1 promoter was the most 
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correlated parameter in male patients (30). For example, mild phenotypic 
symptoms have been reported for patients with an only partially methylated 
full mutation, but without cytogenetic FRAXA expression (31, 32). 
Furthermore, incomplete and complete absence of methylation was found in a 
group of high functioning male patients with cytogenetic expression. In this 
group the presence of FMR1 protein was demonstrated, although in reduced 
amounts (33). It is, however, unclear if this is caused by a lower gene 
expression or by a translation suppression due to the length of the CGG 
repeat. 
The expanded CGG or CCG repeats are predicted to undergo conformational 
changes, which induce de novo methylation (34), thereby stabilizing the 
unusual structures, probably to mark them for repair (35). These structures 
could suppress transcription and replication of the FMR1 gene and so induce 
cytogenetic expression (35). The familial case described in this paper of two 
completely normal brothers with CGG repeat expansion and cytogenetic 
FRAXA expression may provide a clue to both the mechanism of inhibition 
of FMR1 expression and induction of fragile sites. 
RESULTS 
Analysis of the Fra(X) Locus 
The fra(X) family was ascertained through a mentally retarded boy, born 
in 1980 (Fig. 1, 7316). Cytogenetically, 10% FRAXA-site expression was 
found. Further DNA analysis with PstI and EcoRI digested DNA from 
peripheral blood lymphocytes (PBL) revealed expansion of the CGG repeat 
with fragments ranging from apparently normal to full mutation (up to 1500 
repeats; Fig. la+b). A mosaic pattern from premutation to full mutation is 
found in 20% of the fra(X) patients (30, 32, 36), but the pattern of this 
patient is very rare. The mother of the proband had a premutation and a 
normal allele (Fig. la, 7315). Subsequent family analysis revealed 5 more 
carriers, among whom were 2 males having both cytogenetic FRAXA 
expression and a full mutation by DNA analysis (Fig. la+b, 7298 and 7241). 
Surprisingly, these two males were phenotypically normal. In repeated 
experiments, we found 6 and 13% fragile site expression and large repeat 
expansions of 170-340 and 100-1500 copies, respectively (Fig. la). 
In all mentally retarded patients with similar repeat sizes tested, the CpG 
island in front of the repeat was methylated as a result of which the gene was 
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Fig. 1. Southern blot analysis of genomic DNA. PstI (A) and EcoRI (В) digestions 
of PBL DNA and EcoRI-EagI digestions of PBL (C) and EBV transformed 
blood lymphocyte DNA (D). Half-filled squares indicate males with 
normal phenotype, but with cytogenetic FRAXA expression. A filled 
square indicates a male fragile X patient with mental retardation and 
cytogenetic FRAXA expression. A dotted circle represents an obligate 
female carrier with a normal phenotype. 
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not transcribed. The methylation status of the FMR1 gene was determined in 
this family using the enzymes EcoRI + EagI on DNA from PBL and EBV 
transformed blood lymphocytes (Fig. lc+d). The mentally retarded boy 
showed complete methylation of the full mutation, while the premutation and 
normal bands were unmethylated in PBL DNA (Fig. lc). In contrast, no 
unmethylated bands were detectable in DNA from EBV transformed cells 
(Fig. Id). The expanded FMR1 genes of the mentally normal men were 
entirely unmethylated, both in PBL (Fig. lc) and in EBV transformed blood 
lymphocytes (Fig. Id). As expected, the female carriers in the family showed 
partial methylation of both X chromosomes (Fig. lc+d). 
A difference in repeat length distribution was found in blood DNA (Fig. lc) 
compared with the distribution found in DNA isolated from EBV transformed 
blood lymphocytes (Fig. Id). DNA from the cell line of patient 7316 
contained only two bands left from the full mutation range. Male 7298 had a 
repeat distribution with a tendency to the premutation range, while on the 
other hand the cell line of male 7241 showed an almost single repeat length of 
400 repeats, which is completely in the full mutation range. This shows again 
that EBV transformed cell lines are not always a good representation of the 
variety of different cells with different repeat lengths found in blood and that 
they are the product of a limited number of cells. A difference in methylation 
between PBL and EBV transformed blood lymphocytes was only found for 
the patient 7316. 
Expression of the FMR1 Gene 
Methylation of the FMR1 promoter has been reported to inhibit expression 
of the gene. The expression of the FMR1 gene in the three males with large 
repeat expansions was tested in peripheral and EBV transformed blood 
lymphocytes. As an internal control the level of HPRT transcription was 
determined, and classical fra(X) patients and controls were included for 
comparison. No FMR1 mRNA was detectable in classical fra(X) patients with 
large repeat expansions and a methylated promoter region (data not shown). 
The expression in male 7316 was strongly reduced compatible with classical 
fra(X) patients. The level of FMR1 mRNA in PBL was only slightly higher 
than in EBV transformed blood lymphocytes. The FMR1 mRNA levels in 
males 7298 and 7241 were normal in both cell types. 
We analyzed whether the large repeat had an influence on the (efficiency of) 
translation of the FMR1 RNA. Immunoprecipitation was performed on equal 
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amounts of protein extracted from EBV transformed blood lymphocytes and 
FMRP (FMR1 protein) was determined by Western blotting using Ші-FMRl 
antibodies (22). The same passage of the culture was used as for the DNA 
studies. The FMR1 protein was present in the cells from males 7298 and 7241 
at a reduced level compared to normal controls (Fig. 2). 
7241 
•17315 
7316 
-ШШ 
lOOkDa 
68kDa 
Fig. 2. Western blot analysis of FMRP in EBV transformed lymphocytes using 
polyclonal antibody a734. Pedigree symbols are as in figure 1. 
The fra(X) male 7316 showed no FMR1 protein at all, similar to classical 
fra(X) patients. His mother 7315 had a normal FMRP expression as might be 
expected from a carrier of a premutation. 
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To test whether the lower expression in these males was the result of 
expression in cells with a relatively small expansion and no expression in 
cells with a relatively large expansion, we tested the protein expression by 
immunocytochemistry on individual cells of the EBV transformed blood 
lymphocytes. Expression was found in all cells, but also at a lower level than 
in control cells (Fig. 3). 
• 
В 
• 
\ 
Fig. 3. Immunohistochemical detection of FMRP in EBV transformed lymphocyte 
and blood smears. Cell lines of control cells C49 (A), patient 7316 (B), 
individual 7298 (C) and individual 7241 (D). Blood smears of a control (E) 
and individual 7241 (F). 
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This means that a gene with a repeat length of 400 copies can be transcribed 
and translated (Fig. lb). To evaluate the result of the cell lines, the 
expression of the FMR1 protein in blood was analyzed directly on a blood 
smear of male 7241. Again all cells did show expression of the FMR1 
protein, but again at a level lower than control cells (Fig. 3). 
DISCUSSION 
In this study evidence is presented that expansion of the CGG repeat in 
the FMR1 gene itself, even in the full mutation range, does not cause the 
fra(X) phenotype. It is the first example of a large, unmethylated expanded 
CGG repeat without any clinical consequences. This familial case might be 
exceptional, although it is unknown how many people in the general 
population may carry large repeat expansions. The family was analyzed, 
because of the presence of a mentally retarded grandson, but would have been 
missed otherwise. Even this grandson lacked the physical features of fra(X). 
But despite an extraordinary mosaic CGG repeat pattern, FMR1 mRNA and 
protein levels in PBL were comparable with classical fra(X) patients. 
Variation in severity of mental retardation has been shown previously for 
individual patients with different methylation patterns. Rousseau et al. (31) 
described a male with a full mutation with 40% methylation of the FMR1 
gene; unfortunately, protein expression was not determined. Hagerman et al. 
(33) described three high functioning fra(X) males that had unmethylated 
large repeats and showed reduced protein expression compared with control 
values. They did not show whether normal expression was found in a limited 
number of cells or a reduced expression was found in all cells. Our data 
support the conclusion that a minimum amount of protein is necessary for a 
normal phenotype; it could be speculated that this minimal amount may be 
necessary in every cell or at least in a high percentage of cells. This could 
explain that some of the females with a full mutation are normal and some are 
mentally retarded, although less severely than males with a full mutation, due 
to a skewed inactivation of the normal X chromosome. The amount of protein 
made as shown by immunohistochemistry was lower in blood and in EBV 
transformed blood lymphocytes in the males with the unmethylated full 
mutation compared with controls. However, Feng et al. (37) have shown that 
the amount of FMR1 protein using ß-Tubulin as an internal control can differ 
by a factor of 2. Although the relation between RNA/protein levels and 
clinical status has not been extensively analyzed, it is evident that these 
parameters are most indicative for the expression of the FMR1 gene and, most 
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likely, are best suited for clinical predictions. 
Our data show that there is no obligatory relation between repeat expansion 
and me thy lat ion of the FMR1 gene. This has already been demonstrated for 
normal transmitting males with relatively short repeat expansions (50-200 
CGG repeats), but usually larger expansions lead to complete methylation of 
the FMR1 promoter region. Only a few examples have been reported with 
incomplete or mosaic methylation patterns, providing supporting evidence that 
expansion and methylation can be uncoupled (31, 33). Sutcliffe et al. (20) 
have shown in chorionic villi of a male fetus with a full mutation that no 
methylation of the CpG island was found and that the FMR1 gene was 
transcribed. This again indicates that in absence of methylation, transcription 
of a gene with a full mutation is possible. In the two brothers described in 
this paper, this uncoupling is absolute. Because the mechanism and enzymes 
involved in de novo methylation in humans are still unknown, one can only 
speculate about the factors involved. First, the length of the expanded repeat 
may be a factor. Short expansions do not cause methylation, but large 
expansions in general do. The family described here and the data from others 
(20, 38) showed that no absolute point exists at which methylation takes 
place, but that there may be a gradual scale with intra- and interfamilial 
variation. Secondly, our data show that additional (genetic) factors must play 
a part in the methylation process. In the two brothers no methylation is 
apparent, which means that either the specific methylase is defective or that 
the recognition site(s) of the enzyme is altered or blocked. The detection of 
methylation of the same FMR1 promoter in the grandson favors a role for a 
trans-acting factor. Not much is known about de novo methylation in humans, 
but it would be worthwhile to test other methylated areas for a general, 
beneficial methylation defect in these patients. 
Finally, our data do not support the hypothesis that methylation of expanded 
CGG/CCG repeats is necessary for cytogenetic expression of fragile sites. As 
yet, the molecular basis of four fragile sites (FRAXA, FRAXE, FRAXF, 
FRA16A) has been characterized as expanded CGG/CCG repeats. These 
triplets can be methylated, in contrast to the CTG repeat in myotonic 
dystrophy with a similar repeat length. This latter disorder is not associated 
with a fragile site and, therefore, methylation was thought to play a key part 
in cytogenetic expression of these sites. In the two brothers, described in this 
paper, no methylation of the FMR1 promoter could be observed, but 
cytogenetic expression was still evident. The methylation of only a single 
restriction site was determined and not of the entire repeat, but reports from 
others (39, 40) have shown that the methylation status of this site can be 
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extrapolated to the entire area. 
After finishing the experiments described in this paper conflicting results were 
presented by Feng et al. (41). They used fibroblast subclones of a mildly 
affected patient and showed that despite the presence of normal mRNA levels, 
transcription is diminished from mRNAs with more than 200 repeats. They 
concluded that beyond 200 repeats there is no migration of the ribosome 
along the repeat. However, we show that in a cell line, almost exclusively 
containing cells with a repeat of 400 CGG copies, translation of FMR1 
mRNA takes place in all cells although at a reduced level compared with 
controls. Also expression was found in all cells in a blood sample from the 
same individual (Fig. 3). This expression of the FMR1 protein in all cells can 
explain the normal phenotype of this individual. 
MATERIALS AND METHODS 
Human Subjects 
Case 1 (7316). The 14-year-old proband was mentally retarded since 
childhood, but there was no family history of mental retardation. Physical 
examination at the age of 14 showed a boy with normal body proportions. No 
macrocephaly (occipito frontal circumference (OFC) 56 cm (percentile 75-90) 
and no macrognathia was present. His palate and ears were normal (ear 
lengths 6,5 cm). He revealed mild hypermobility of distal joints and a soft 
skin. The external genitalia were small (testes length 2,5 cm) with little 
pubertal hair development. Psychological testing at the age of 13 years 
showed a friendly and cooperative boy with good verbal performance. IQ 
testing at the same age showed a verbal IQ of 64 and a performance IQ of 53 
(WISC-R). His behavior was normal without the typical manifestations of 
fra(X). 
Case 2 (7315). The 36-year-old mother of the proband is phenotypically and 
mentally normal. She studied nursing and is successfully employed in this 
profession. 
Case 3 (7241). The 72-year-old maternal grandfather of the proband is in 
good health. Physical examination at the age of 72 revealed a normal 
phenotype. No macrocephaly was present (OFC 57,2 cm; percentile 75) and 
his forehead was not broad. His ears had lengths of 7,6 and 7,7 cm, but 
normally shaped. His face was not elongated. No other clinical abnormalities 
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were found. He refused testicle examination. He has good eye contact and 
also lacks the other behavioral manifestations of the fra(X) syndrome. He 
attended high school and became managing-director of a family company of 
about 100 employees. His mental status could be described as intelligent. 
Case 4 (7298). This is the 74-year-old grand-uncle of the proband. His head, 
face and ears were normally shaped, but he refused detailed physical 
examination. He had no behavioral manifestations of fra(X). School training 
was similar to his brother (7241). He was a college student for 3 years after 
which he became managing-director of the family company. His mental status 
could also be described as intelligent. 
Cytogenetic Studies 
Chromosomes were studied from peripheral whole blood lymphocytes. 
Details of the methodology were described previously (42). Cell cultures were 
initiated using Chang medium with multiple FRAXA induction systems 
(FUdR and Thymidine) as described (43). Ten days before harvesting, the 
long term culture was subcultured on RPMI-1640. A maximum of 200 cells 
of each sample were examined for the presence of a fra(X) chromosome. 
DNA and RNA Studies 
Southern blot analysis of DNA, extracted from peripheral blood, was 
performed according to standard procedures (44) with probe pA0365 (45). 
The methylation status of the FMR1 gene was determined by double digests 
with the methylation sensitive restriction enzyme EagI as has been described 
before (32). RNA was extracted from EBV transformed cell lines using 
standard procedures (44). The ratio between HPRT and FMR1 mRNA was 
determined, using the protocol of Pieretti et al. (19). Our modifications 
involve the use of fluorescently labeled PCR primers, followed by analysis on 
a sequencing gel, using the GeneScanner Software (ABI, Foster City). 
Protein Studies 
Polyclonal antibodies were raised in rabbits against a GST-FMR1 fusion 
protein (a734) (22) and used in immunoprecipitations and Western blotting. 
Immunoprecipitation, gel electrophoresis and Western blotting were 
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performed as described (22), with the exception of using 125I protein A instead 
of alkaline phosphatase conjugated goat anti rabbit IgG to detect the 
polypeptides. Immunocytochemistry on EBV transformed lymphocytes and on 
whole blood smears was performed as described (46, 47) using monoclonal 
antibody 1A (23). 
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CHAPTER 10 
GENERAL DISCUSSION 

Inheritance of Fra(X) 
Although there is no doubt that the fra(X) syndrome is an X-linked disease 
there are two unusual genetic characteristics. 
Firstly, an unusual large fraction of the male carriers of the FMR1 gene is 
unaffected. Although transmission of the fra(X) through unaffected men is well 
known (Webb et al., 1981; Fryns and Van den Berge, 1982; Young et al., 
1986), the incidence of male transmission has always been underestimated. 
Extensive family studies have demonstrated grandpaternal transmission in nearly 
half of the cases (Chapter 2). Apparently, for an X-linked disorder, there is an 
unusual lack of phenotypic expression in carrier males who are, therefore, called 
" Normal Transmitting Males" (NTMs). The implications of this phenomenon 
are tremendous as all daughters of these nonpenetrant males are nonexpressing 
obligate carriers. However, nearly 40 percent of the grandchildren, male and 
female, appear to be affected (fig. 1). The "Sherman paradox" refers to these 
marked differences in penetrance of the mutation in subsequent generations 
(Sherman et al., 1985). 
Secondly, it was found that sibs of NTMs are less likely to be affected than sibs 
of affected males (Sherman et al., 1985; Smits et al., 1992). These intriguing 
questions have, to a large extent, been solved in the last few years. This has led 
not only to a better understanding of the fra(X) syndrome but also to a new 
genetic concept, the dynamic mutation mechanism. 
Repeat Instability in Genetic Disorders 
A considerable proportion of the human genome contains repeated DNA. 
These repeats vary from single bases up to fragments of 40 bases in length 
(Beckmann and Weber, 1992). The most common simple repeats, defined as 
microsatellites are dinucleotide repeats, particularly (CA)n (Weber, 1990), which 
are located at about 50,000 distinct positions throughout the human genome. 
There are many other such simple tandem repeats, encompassing mono-, tri-, 
tetra-, and pentanucleotide repeating units (Sutherland and Richards, 1995). 
Of these repeats, some trinucleotide repeat stretches appear to be particularly 
unstable in various genetic disorders. Presently, 8 diseases are associated with 
triplet repeat expansions (Oostra and Halley, 1995)(fig. 2). 
Five folate-sensitive fragile sites (FRAXA, FRAXE, FRAXF, FRA11B and 
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Syndrome Gene Chr Triplet repeat instability 
Fragile X syndrome 
FRAXE MR 
FRAXF 
FRA11B 
FRA16A 
В SMBA 
Huntington disease 
Spinocerebellar ataxia I 
Dentatorubralpallidoluysian 
atrophy 
Haw River syndrome 
Machado-Joseph disease 
Spinocerebellar ataxia 3 
Myotonic Dystrophy 
(CGG)n 
FMR1 Xq27.3 >20гД 
FMR2 Xq28 S0-200\, 
? Xq28 
CBL2 11q23.3 
? 16p11 
ORF 
(CAG)n 
AR 
HD 
SCAI 
Xq11-12 
4p16 
6p22 
DRPLA1 
> 12p12 
ORF 
HRS 
MJD 
SCA3 
DM 
14q23 
19q13 ORF 
Fig. 2. Schematic diagram of dynamic mutations associated with genetic diseases. 
Phenotypes with different repeat sizes: (areas with horizontal lines) normal; 
(area with diagonal lines) normal (premutation); (areas with vertical lines) 
affected; (black area) affected (congenital form). (Adapted from: Oostraand 
Hally, 1995). 
FRA16A) are all composed of polymorphic (CGG) trinucleotide repeats. Studies 
of FRAXE patients have shown that methylation of CpG residues close to the 
CGG repeat is associated with mental impairment, similar as seen in fra(X) 
syndrome (Knight et al., 1993, 1994). However, apart from mild mental 
retardation, affected males and females did not show a specific phenotype. In 
addition, some affected FRAXE males have affected daughters (Hamel et al., 
1994). The remaining three fragile sites, FRAXF (Hirst et al., 1993), FRA16A 
(Nancarrow et al., 1994) and FRAI IB (Jones et al., 1995), contain 
hypermethylated and unstable CGG repeats which are not associated with any 
clinical phenotype. It seems likely that they are not related to the expression of 
a gene. Jones et al. (1995) suggested an association of a heritable fragile site and 
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chromosome breakage in vivo as they discovered breakage at FRA IIB in a 
number of patients with Jacobson syndrome (llq-). 
Studies on FRA16A indicated that methylation might be a consequence of the 
CGG expansions as the fragile site mutation is in a region of the genome which 
is normally not methylated (Nancarrow et al., 1994). However, our data show 
that there is no obligatory relationship between methylation of the FMR1 gene 
and CGG repeat expansion (Chapter 9). Thus, additional factors must play a role 
in the methylation process. 
Expansions of (CAG)n trinucleotide repeats, encoding polyglutamine tracts, 
appear to be associated with five neurodegenerative disorders: Spinal and bulbar 
muscular dystrophy (SMBA) (Xqll-12) (La Spada et al., 1991), Huntington's 
disease (4pl6) (Huntington's Disease Collaborative Research Group, 1993), 
Spinocerebellar ataxia type 1 (6p22) (Orr et al., 1993) and type 3 (14q24) 
(Kawaguchi et al., 1994), Dentorubal-pallidoluysian atrophy (12pl2) (Koide et 
al., 1994). Although the exact mechanism by which such molecular events lead 
to neurodegeneration is still unknown, it has been suggested that a protein with 
an expanded polyglutamine tract may lead to a gain of function or to a dominant 
negative effect which results from aberrant interaction with itself, its normal 
target or a new gene product (Banfi et al., 1994). 
Myotonic dystrophy was the first autosomal disease identified by amplification 
of a trinucleotide repeat. Amplification of the CTG tract (equivalent to CAG) 
above the threshold length of 38 repeats results in abnormal mRNA stability (Fu 
et al., 1993; Sabouri et al., 1993) and the extremes of the clinical phenotype 
correlates with the size of the mutation (Brook et al., 1992; Harley et al., 1992; 
Hunter et al., 1992). Animal equivalents of the trinucleotide repeats involved in 
human disease encode shorter length repeats, a greater stability and lower degree 
of polymorphism which suggests that the mechanism of dynamic mutations may 
largely be restricted to the human genome (Sutherland and Richard, 1995). 
Microsatellite instability has also been noted as a frequent genetic alteration in 
human cancer cells (Ionov et al., 1993; Thibodeau et al., 1993; Peltomaki et al., 
1993; Wooster et al., 1994). Instability of mono-, di- and trinucleotide repeats 
appear to be associated with various inherited cancer syndromes (reviewed by 
Richards and Sutherland, 1994). Tract instability of simple repeats may be a 
consequence of either an increased rate of DNA polymerase slippage or a 
decreased efficiency of mismatch repair (Strand et al., 1993). 
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Genetic Background and CGG Repeat (In)stability 
How and how often fra(X) premutations arise in the general population is 
still largely unknown. Haplotype analyses with nanking (CA)n markers have 
revealed linkage disequilibrium between fra(X) and normal X chromosomes, 
which indicates a limited number of predisposing normal alleles (Richards et al., 
1992; Smits et al., 1993; Macpherson et al., 1994). 
We have searched for evidence of paternal or maternal genetic components 
outside the FMR1 gene, which might predispose for repeat instability. If paternal 
factors contributed to the degree of expansion of the maternally transmitted CGG 
repeat, length variation of the repeat between halfsibs, having different fathers, 
would be expected. To assess the paternal contribution to repeat expansion, we 
have analyzed fifteen half sisters/brothers in five families (fig. 3). Comparison 
of the CGG repeat length between the halfsibs demonstrated either a premutation 
or a full mutation in all the paired samples, independent of the paternal 
inheritance (Smits et al. unpublished data). These results indicate that only 
maternal factors influence CGG repeat stability. 
It could also be speculated that the non-mutated X chromosome in fra(X) carrier 
females might influence the stability of the CGG repeat. Heterozygotes were, 
therefore, compared according to the maternal origin of the non-mutated X 
chromosome in sisters carrying the paternally inherited premutation. We found 
in two out of six obligate carriers (fig. 1, 11:3 and 11:21) that expansion from a 
premutation to a full mutation in the offspring did not occur, irrespective of 
which maternal inherited X chromosome was present (Smits et al. unpublished 
observations). Recent evidence suggests that the instability probably is a function 
of the composition of the trinucleotide repeat. The FMR1 trinucleotide repeat 
array is a compound structure of (CGG)n with some interruptions by AGG 
triplets at the 5' end of the repeat, while the 3' end shows the length variations 
with the longest arrays of perfect CGG repeats. Sequence analysis of normal 
alleles revealed haplotype-specific variation of the repeat (Kunst and Warren, 
1994; Hirst et al., 1994). Alleles in the normal size range but having at least 24 
perfect CGG repeats in the 3' end appear more frequently on haplotypes 
overrepresented among fra(X) chromosomes. Similar data were found upon 
sequence analysis of premutations, 63 percent had no interruptions of AGG 
triplets, while 37 percent had only one AGG (Zhong et al., 1995). These data 
indicate that the stability of repeats in the normal range may be dependent on the 
nature of the interspersed AGG triplets. 
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Fig. 3. Pedigrees with halfsibs having different fathers. Solid symbols denote 
affected individuals. The presence of the full mutation, premutation and a 
normal sized FMR1 gene as analysed by Southern blotting are indicated by 
" > > ", " > ", and "n" respectively. The arabic numbers refer to the length 
of the CGG fragment as determined by PCR. 
Diagnostic Issues of the Fra(X) Syndrome 
The discovery of the molecular basis of the fra(X) syndrome has had a major 
impact on the diagnosis of the disease. The vast majority of fra(X) patients 
appear to have a dramatic increase in length of the CGG repeat at the 5' end of 
the FMR1 gene. However, some patients have been described who showed 
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typical clinical features of the fra(X) syndrome without amplification of the CGG 
repeat and/or cytogenetic expression. In these cases the patients appeared to have 
a partial de novo deletion (Gedeon et al., 1992; Wöhrle et al., 1992; Tar letón 
et al., 1993; Gu et al., 1994; Trottier et al., 1994; Lugenbeel et al., 1995; Quan 
et al., 1995), a familial deletion (Meijer et al., 1994) or a point mutation in the 
FMR1 gene (De Boulle et al., 1993). All these alterations resulted in silencing 
of the FMR1 gene with the same phenotypic consequences. Although the 
incidence of de novo deletions seems to be low, we have identified a family with 
two affected brothers (fig. 4, 11:4 and 11:5) both carrying a deletion of the CGG 
repeat, whereas an other mentally impaired relative exhibits an amplification of 
the CGG repeat (11:2). Linkage analysis was compatible with the mutated X 
chromosome being the same in both family branches (Smits et al. unpublished 
observations). These data suggest that the deletion of the CGG repeat is 
secondary to its amplification, in line with previous observations in 4 patients all 
expressing a full mutation besides the presence of a deletion (De Graaf f et al., 
1995). 
That the fra(X) syndrome may be caused by amplification of the CGG repeat, 
deletion of the CGG repeat, or a point mutation has the practical consequence 
that no single DNA analysis technique is sufficient to detect all the possible 
mutations. As the point mutations appear to be very rare, DNA sequence 
analysis is only carried out if there are very convincing clinical signs. For 
screening purposes, PCR analysis of the CGG repeat is widely used. This 
method will detect amplifications and deletions of the CGG repeat in males. This 
has to be followed up by Southern blot analysis to distinguish between the two 
latter possibilities. If in females only 1 PCR fragment is seen, Southern blot 
analysis has to be performed also, to establish whether or not two normal sized 
alleles are present. 
We have shown (Chapter 9) that methylation of the promoter region inhibits 
expression of the FMR1 gene and that repeat expansion itself is not sufficient for 
expression of the fra(X) phenotype. In case of a discrepancy between the mental 
status and the CGG repeat length, the methylation status should be assessed. 
Unfortunately, methylation tests are not useful for prenatal diagnosis. Iida et al. 
(1994) have compared the extent of methylation in fetal brain, cord blood, 
chorionic villi and placenta and found a discrepancy between embryonic and 
extra-embryonic tissues. These observations are in agreement with those of 
Sutherland et al. (1991) and Sutcliffe et al. (1992) who showed that villous 
samples do not exhibit the ultimate methylation state. Indeed it has been found 
that chorionic villi of males with a full FMR1 mutation, taken before the 11th 
week of gestation, may show an unmethylated DNA pattern (Oostra, personal 
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11:4 11:5 
Affected brothers (11:4 and 11:5) are both carrying a deletion of the CGG 
repeat in the FMR1 gene. Southern blot analysis of genomic DNA digested 
with EcoRI and hybridized with probe PA0365 showed the familial deletion 
(lane 4 and 5) as well as an expansion (lane 2) of the CGG repeat in the 
FMR1 gene. 5.2 kb shows a fragment of normal length. S= dispersed 
segment from which this smear developed upwards. 
communication). Recently, an antibody test on bloodsmears for diagnosing 
fragile X syndrome was developed (Willemsen et al., 1995). This test is based 
on presence or absence of FMRP (FMR1 Protein). A similar test on chorionic 
villi for prenatal diagnosis of fragile X syndrome is validated. An example of 
this test is shown in figure 5. 
Fig. 5. FMRP expression in chorionic villi (c.v). using the indirect 
immunoperoxidase technique on cryostat sections. A = c.v. (12.5 weeks) 
control fetus. В = c.v. (12.5 weeks) affected male fetus. The dark staining 
in the cytotrophoblast cells from control villi (A) indicates the presence of 
FMRP, whereas in the cytotrophoblast cells from the affected male fetus (B) 
no FMRP could be observed. (FMRP test provided by Dr. R. Willemsen). 
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Several tissues, including brain, of this male fetus did not express any FMRP 
(Oostra, personal communication). More studies on fetal cells in case of 
termination, and in cord blood/peripheral blood after birth, should be done to 
support this preliminary result. 
Benefits of Active Genetic Counseling in Fra(X) Families 
Relatives of identified fra(X) syndrome patients should be informed about 
genetic risk factors and, subsequently, given access to carrier-testing. It is 
important to note that usually most individuals are not aware of the presence of 
a fra(X) mutation in their family. Therefore, it is an important task for the 
genetic counseling clinic to perform systematic and careful active genetic 
counseling. According to this active approach, we have studied 100 
multigenerational fra(X) families in the past fifteen years. The mutation could 
be deduced or directly detected in more than 700 carriers. Excluding the index 
patients, 480 female carriers (150 affected) and 220 male carriers (170 mentally 
retarded and 50 NTMs) were identified (unpublished observations). Previously 
undiagnosed mentally retarded individuals in these families could readily be 
diagnosed. An early diagnosis does not only prevent unnecessary medical 
investigations but also makes a timely start of a therapeutic strategy possible. 
Particularly, physicians should be in a position to apply appropriate therapies 
which may include medication, language and occupational therapy, counseling 
and special education, as needed (Hagerman et al., 1992). 
For parents of fra(X) patients and their relatives, it is extremely important to 
have the opportunity to make a reproductive choice based on adequate 
information concerning diagnosis, prognosis, recurrence risk and the availability 
of post- and prenatal diagnosis. As long as they are informed, the primary aim 
of active genetic counseling has been achieved. The secondary effects of genetic 
counseling of females at risk on decisions about childbearing may lead to the use 
of prenatal tests and to reduction in birth of affected individuals (Turner et al., 
1992). 
Since 1991, we performed prenatal tests, based on direct detection of the CGG 
repeat length, in 25 cases using chorionic villus sampling at the end of the first 
trimester of pregnancy. A full FMR1 mutation was found in 10 cases and in all 
of them the parents opted for termination of the pregnancy. The decision 
whether or not to terminate was (and still is) very difficult, in particular, in case 
of a female fetus with a full mutation, as the incomplete penetrance has to be 
taken into account. As long as it is impossible to accurately predict whether and 
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to which degree a female fetus with a full mutation will be affected, this question 
will remain among the most difficult ones for all families concerned (Fryns, 
1989). 
Population Based Screening for Fra(X) Syndrome 
As the population frequency of the fra(X) gene is quite high, different 
scenarios for population based screening programs have been proposed. 
Screening of all pregnant women would, in theory, be a comprehensive approach 
of carrier detection for the fra(X) syndrome. Apart from ethical considerations 
and practical limitations, the main arguments against screening of all pregnant 
women are (i) that precise prevalence figures for the premutation in the 
population are lacking and (ii) that there is a lack of accurate information about 
the overlap (grey zone) between extended normal alleles and small premutations. 
Although there is evidence that the prevalence of premutations might be high 
(Rousseau et al., 1993, 1995; Reiss et al., 1994), it is proposed by the American 
College of Medical Genetics (ACMG) (1994) that additional information on the 
repeat stability has to be obtained from populations unselected for the fra(X) 
syndrome. We agree, as stated by ACMG (1994), that screening of pregnant 
women is not indicated until these matters have been clarified. 
A less controversial approach would be to search for full mutations in newborn 
males, as was suggested by Young (1993). Direct detection of the CGG repeat 
length is very accurate and has the advantage that an accurate prognosis can be 
given, supplemented by the offer to investigate the extended family. However, 
this DNA test is still labour-intensive, technically demanding and expensive to 
perform on a large scale basis (Bonthron and Strain, 1993). An alternative assay 
could be to test the presence or absence of the gene product FMRP (Oostra and 
Halley, 1995). This rapid antibody test, suitable for screening of large numbers 
of individuals, may be easy to combine with e.g. the PKU (phenylketonuria) 
test. 
The ACMG (1994) proposed that fra(X) screening should be considered for 
individuals of either sex with mental retardation, developmental delay or autism, 
especially if they have (a) any physical or behavioral characteristics reminiscent 
of fra(X) syndrome, (b) a family history suspect for fra(X) syndrome or (c) male 
or female relatives with undiagnosed mental retardation. Several studies on 
selected populations of mentally retarded individuals have confirmed that fra(X) 
patients account for a substantial proportion of residential patients (Blomquist et 
al., 1982, 1983; Bundey et al., 1985; Kähkönen et al., 1986; Fryns, 1989). In 
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a study of 350 mentally retarded institutionalized adult males we found 10% 
positive for the fra(X) syndrome thus far. Figure 6 gives an idea of the variety 
of clinical features of patients in such an institute. 
Fig. 6. Picture of institutionalized adult males, showing a large variety of clinical 
features. Three of them were identified as having fra(X) syndrome. 
Among this latter group, 5 persons were selected for fra(X) repeat testing based 
on clinical features only and, subsequently, three of them were identified as 
having the fra(X) syndrome. 
In the Netherlands about 125000 individuals are mentally impaired, including 
35000 institutionalized patients (NVGZ, 1995). Fryns et al. (1984) proposed that 
nearly 3 percent of the total mentally retarded population may be attributed to 
the fra(X) syndrome. Supporting evidence for the high prevalence of the fra(X) 
syndrome came from Webb et al. (1986, 1991) and Turner et al. (1986, 1992). 
In a population of 1.2 million in Australia, 2000 intellectually handicapped 
persons were screened. The estimated prevalence rates for the fra(X) syndrome 
with all degrees of mental impairment were 1:2600 for males and 1:4200 for 
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females. Based on these estimations, approximately 4500 fra(X) patients can be 
predicted for the Netherlands. Up to now, less than 500 of all fra(X) male 
patients have been diagnosed (Oostra, in preparation). With regard to this result, 
the recommendation can be made that a preventive screening program in 
mentally retarded populations should be performed in order to identify all fta(X) 
patients. Every identified fra(X) index patient may serve as a starting-point for 
active genetic counseling of relatives at risk. 
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SAMENVATTING 
Mentale retardatie, ofwel een verstandelijke handicap, komt relatief vaak voor. 
In Nederland zijn ongeveer 125000 mensen verstandelijk gehandicapt waarvan er 
vermoedelijk 4500 lijden aan het zogenaamde fragiele X (fra(X)) syndroom. Naast 
mentale retardatie kent het fra(X) syndroom ook enkele niet specifieke lichamelijke 
kenmerken zoals vergrote testikels, een lange smalle gelaatsvorm en grote 
afstaande oren. Kenmerkend is ook het typische taal- en spraakgebruik met een 
betekenisloze herhaling van vooral vragende taaluitingen. Bovendien vertonen veel 
patiënten een overbeweeglijk gedrag, ze hebben concentratiemoeilijkheden en ze 
zijn schuw in sociale situaties, waarbij het vermijden van oogcontact opvalt. 
Het fra(X) syndroom dankt zijn naam aan een fragiele plaats op het uiteinde van de 
lange arm van het X chromosoom. Al in 1969 werd ontdekt dat er een verband 
bestaat tussen het voorkomen van deze fra(X) plaats en mentale retardatie. Nadat 
bijna 10 jaar later bekend was geworden dat een laag foliumzuurgehalte bij het 
kweken van cellen vereist is om deze fragiele plaats licht-microscopisch zichtbaar 
te maken, kon diagnostiek op basis van chromosomenonderzoek en vervolgens 
erfelijkheidsvoorlichting in fra(X) families worden verricht. Diagnostiek door 
middel van chromosomenonderzoek bleek echter in bepaalde gevallen niet 
betrouwbaar. Ofschoon fra(X) patiënten wel goed detecteerbaar waren bleek 
dragerschap bij gezonde personen niet of moeilijk vast te stellen. 
Sinds 1986 werd naast het chromosomenonderzoek ook gebruik gemaakt van DNA-
koppelingsonderzoek. Hiermee kon indirect de waarschijnlijkheid dat het fra(X) 
gen aanwezig was bepaald worden zonder dat het betrokken gen zelf bekend was. 
Dit was mogelijk door kleine variaties in het DNA (merkers) te gebruiken die in de 
directe nabijheid van het fra(X) gen waren gelegen en die duidelijk samen met het 
ziektebeeld overerfden in de familie. Hierdoor verbeterde de betrouwbaarheid van 
de bestaande onderzoeksmethode aanzienlijk en vals negatieve uitslagen op basis 
van het chromosomenonderzoek konden veelal (tijdig) worden gecorrigeerd. 
In 1991 leidde moleculair genetisch onderzoek tot de isolatie van het FMR1 gen 
(fragiele X mentale retardatie). Aan het begin van dit FMR1 gen werd een 
specifieke basevolgorde aangetroffen bestaande uit een repeterende volgorde van 
drie DNA bouwstenen (CGG-triplet (C(Cytosine) G(Guanine) G(Guanine)). Het 
FMR1 gen bevat in normale situaties een aantal van 6 tot 50 CGG-triplets. Mutaties 
in het FMR1 gen blijken het gevolg te zijn van een (sterk) toegenomen aantal van 
deze CGG-triplets. Er zijn twee typen FMR1 gen mutaties te onderscheiden: (i) een 
kleine verandering (premutatie) met een lengte tussen 50-200 CGG-triplets. Deze 
heeft geen klinische consequenties, (ii) een grote verandering (volledige mutatie) 
waarbij aanzienlijk meer dan 200 CGG-triplets voorkomen. Dit grote aantal CGG-
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triplets leidt vrijwel altijd tot inactivatie van het FMR1 gen. Hierdoor komt het 
FMR1 proteïne (FMRP), waarvoor dit gen codeert en dat van belang is voor een 
normale verstandelijke ontwikkeling, niet of maar gedeeltelijk tot expressie. Dit 
heeft het fra(X) fenotype (klinische verschijnselen passend bij het fra(X) syndroom) 
tot gevolg. Nadat de lengte van het betreffende deel van het FMR1 gen, dat direct 
afhankelijk is van het aantal CGG-triplets, nauwkeurig kon worden bepaald werd 
het mogelijk deze als directe diagnostische test toe te passen. De sensitiviteit 
(percentage zieke personen met een positief testresultaat) van de directe DNA test 
bleek zeer hoog zowel bij mannen als vrouwen. De specificiteit (percentage niet-
zieke personen met een negatief testresultaat) van deze test bij vrouwen was echter 
matig omdat een belangrijk deel van de vrouwen met een volledige fra(X) mutatie 
mentaal normaal functioneerde. Derhalve was de voorspellende waarde bij 
prenatale diagnostiek, in geval van een vrouwelijke foetus met een volledige 
mutatie, beperkt. 
De ontdekking van de verschillende typen mutaties in het FMR1 gen verklaarde ook 
de etiologie en het bijzondere overervingspatroon van het fra(X) syndroom. Het 
was opmerkelijk dat de hoge incidentie van het fra(X) syndroom in de bevolking 
niet verklaard kon worden door het frequent ontstaan van nieuwe mutaties. In alle 
bestudeerde families kon de aanwezigheid van een premutatie in het FMR1 gen 
steeds in voorafgaande generaties worden aangetoond. Door de overerving van een 
nauw gekoppelde genetische merker te bestuderen, in fra(X) families die onderling 
verwant waren, bleek dat de fra(X) mutatie gedurende vele generaties voorkwam. 
Er zijn zelfs aanwijzingen dat fra(X) patiënten in meerderheid afstammen van een 
relatief kleine groep gemeenschappelijke voorouders. Wat de plotselinge toename 
van het aantal CGG-triplets bij patiënten veroorzaakt is niet met zekerheid 
vastgesteld. Het lijkt waarschijnlijk dat over meerdere generaties kleine 
veranderingen optreden in de repeterende CGG-volgorde en lengte van het FMR1 
gen, waardoor de stabiliteit van dit DNA-fragment afneemt. 
Het overervingspatroon van de fra(X) mutatie bleek in sterke mate bepaald te 
worden door het geslacht van de ouder. Mannelijke dragers van een premutatie 
gaven deze premutatie vrijwel onveranderd door aan dochters. Deze dochters 
vertoonden evenals hun vaders geen fra(X) fenotype, maar bleken zelf wel zonen 
en dochters te hebben met een premutatie dan wel een volledige mutatie. De 
penetrance (frequentie waarmee bij dragers van de mutatie het verwachte fenotype 
tot uiting komt) was bij zonen 85%. Deze incomplete penetrance kon verklaard 
worden door de aanwezigheid van premutaties. De penetrantie bij dochters bleek 
een veelvoud te zijn van wat literatuurgegevens vermeldden, namelijk 64%. Deze 
beduidend lagere penetrantie dan bij zonen werd veroorzaakt doordat er naast 
dochters met een premutatie ook dochters voorkwamen met een volledige fra(X) 
mutatie zonder dat dit leidde tot het fra(X) fenotype. Dit lijkt verband te houden 
met het proces van lyonisatie (naar willekeur wordt in alle cellen één van de twee 
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X-chromosomen geïnactiveerd). Als in de meeste cellen het X-chromosoom met 
een volledige mutatie in het FMR1 gen geïnactiveerd werd had de aanwezigheid 
van een volledige fra(X) mutatie geen nadelige gevolgen voor de mentale 
ontwikkeling. In gezinnen waarin de moeder draagster was van een volledige 
fra(X) mutatie werd de hoogste penetrance vastgesteld. Over het algemeen 
vertoonden meisjes in vergelijking met jongens met het fra(X) syndroom een 
minder grote ontwikkelingsachterstand die zich beperkte tot voornamelijk 
leermoeilijkheden. 
Een wetenschappelijk interessante bevinding was de totale afwezigheid van het 
fra(X) fenotype bij 2 broers met een volledige fra(X) mutatie. Deze situatie toonde 
aan dat er geen absolute relatie bestaat tussen het aantal toegenomen CGG-triplets 
en de inactivatie van het FMR1 gen. Expressie van het FMRP bleek ook bij 
aanwezigheid van een volledige fra(X) mutatie plaats te kunnen vinden en cruciaal 
te zijn voor een normale mentale ontwikkeling. Een recent ontwikkelde 
diagnostische test maakt het thans mogelijk om op relatief eenvoudige en snelle 
wijze de aan- of afwezigheid van het FMRP vast te stellen. 
Tenslotte heeft het hier beschreven onderzoek aangetoond dat de primaire 
doelgroep voor onderzoek naar het voorkomen van de fra(X) mutatie mentaal 
geretardeerden zijn. Mede door de intensieve samenwerking met artsen die 
werkzaam zijn in de zwakzinnige zorg kon bij ruim 100 index patiënten het fra(X) 
syndroom worden gediagnostiseerd. Door familieleden van deze fra(X) patiënten 
actief te benaderen om hen erfelijkheidsvoorlichting te geven konden velen 
vroegtijdig op de hoogte gebracht worden van een mogelijk risico op kinderen met 
het fra(X) syndroom. Vrijwel iedereen stelde onderzoek naar het voorkomen van 
drager-/draagsterschap van de fra(X) mutatie op prijs. Bij ruim 700 familieleden 
van fra(X) patiënten werd door middel van DNA-onderzoek drager-/draagsterschap 
aangetoond of afgeleid. DN A-diagnostiek bood ook voldoende zekerheid om aan 
draagsters prenatale diagnostiek aan te bieden. Voor een aantal draagsters van een 
fra(X) mutatie was de optie van prenatale diagnostiek met de mogelijkheid van 
selectieve abortus aanvaardbaar. In deze sterk belaste families konden echter ook 
zeer velen gerustgesteld worden ten aanzien van een verhoogd risico op kinderen 
met een verstandelijke handicap. Bij hen werd op basis van betrouwbaar 
diagnostisch onderzoek drager-/draagsterschap van de familiair voorkomende 
fra(X) mutatie uitgesloten. 
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STELLINGEN 
behorend bij het proefschrift 
"The fragile X syndrome: genetic and diagnostic aspects" 
1. Er is geen direct verband tussen de lengte van de CGG repeat in het FMRl gen en 
het fragiele X fenotype (Dit proefschrift). 
2. Systematisch onderzoek in fra(X) families naar dragerschap van mutaties in het 
FMRl gen heeft de voorkeur boven populatiescreening (Dit proefschrift). 
3. De voorspellende waarde van de directe DNA-test, bij een vrouwelijke foetus met 
een volledige fra(X) mutatie, is beperkt (Ditproefschrift). 
4. Door het foundereffect bij het fra(X) syndroom zijn nagenoeg alle dragers/draagsters 
van FMRl gen mutaties in Nederland op te sporen. 
5. Non-directieve erfelijkheidsadvisering aan verstandelijk gehandicapten met 
kinderwens stelt de counseler voor een dilemma. 
6. Meer inspanning vanuit de klinische genetica, om familieleden "at risk" tijdig te 
informeren, zou veel ernstig leed kunnen voorkomen. 
7. In the strictest sense of the word dynamic mutations are not really mutations, but 
new and different mechanisms that result in disease (Hall, 1994 Growth Genetics & 
Hormones: Vol. 10 No.4:11). 
8. Intellectual handicaps are costly both emotionally and financially, and the costs span 
'a life time (Turner et al., 1986; New England Journal of Medicine: 315:607-609). 
9. Een hoge matemale leeftijd vergroot de kans op het krijgen van een gezond kind, 
wanneer er sprake is van een mannelijke drager van een gebalanceerde 
chromosomale translocatie t(21q21q) of t(22q22q). 
10. Bij het spelen van tennis biedt het net de meeste tegenstand. 
Nijmegen, 18 april 1996 A.P.T. Smits 



